|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
ES2434961T5
(es)
*
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
US6998267B1
(en)
|
1998-12-09 |
2006-02-14 |
The Dow Chemical Company |
Method for manufacturing glycoproteins having human-type glycosylation
|
|
ATE464907T1
(de)
|
1999-02-17 |
2010-05-15 |
Csl Ltd |
Immunogene komplexe und methoden in bezug auf diese
|
|
EP2251426A1
(en)
|
1999-10-26 |
2010-11-17 |
Stichting Dienst Landbouwkundig Onderzoek |
Mammalian-type glycosylation in plants
|
|
EP2264072A1
(en)
*
|
2000-04-13 |
2010-12-22 |
The Rockefeller University |
Enhancement of antibody-mediated cytotoxicity.
|
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
|
US7598055B2
(en)
*
|
2000-06-28 |
2009-10-06 |
Glycofi, Inc. |
N-acetylglucosaminyltransferase III expression in lower eukaryotes
|
|
US8697394B2
(en)
*
|
2000-06-28 |
2014-04-15 |
Glycofi, Inc. |
Production of modified glycoproteins having multiple antennary structures
|
|
AU2001276842B2
(en)
*
|
2000-06-28 |
2007-04-26 |
Glycofi, Inc. |
Methods for producing modified glycoproteins
|
|
WO2002057468A2
(en)
|
2001-01-19 |
2002-07-25 |
The Dow Chemical Company |
Method for secretory production of glycoprotein having human-type sugar chain using plant cell
|
|
JP2005500018A
(ja)
*
|
2001-04-02 |
2005-01-06 |
アイデック ファーマスーティカルズ コーポレイション |
ＧｎＴＩＩＩと同時発現する組換え抗体
|
|
RU2321630C2
(ru)
|
2001-08-03 |
2008-04-10 |
Гликарт Биотекнолоджи АГ |
Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
|
|
CA2471092A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Antigenics Inc. |
Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
|
|
US20040132101A1
(en)
*
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
NZ534881A
(en)
|
2002-03-19 |
2006-09-29 |
Plant Res Internat B |
Mammalian GnTIII expression in plants
|
|
CA2799805C
(en)
|
2002-03-19 |
2016-05-17 |
Stichting Dienst Landbouwkundig Onderzoek |
Optimizing glycan processing in plants
|
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
CL2003002461A1
(es)
|
2002-11-27 |
2005-01-07 |
Dow Chemical Company Agroscien |
Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas.
|
|
EP1590437A4
(en)
*
|
2003-01-24 |
2008-06-18 |
Agensys Inc |
NUCLEIC ACIDS SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER AND CORRESPONDING PROTEINS NAMED 254P1D6B
|
|
US7332299B2
(en)
|
2003-02-20 |
2008-02-19 |
Glycofi, Inc. |
Endomannosidases in the modification of glycoproteins in eukaryotes
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
ES2672640T3
(es)
*
|
2003-11-05 |
2018-06-15 |
Roche Glycart Ag |
Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
|
|
WO2005077981A2
(en)
*
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
WO2005080432A2
(en)
|
2004-02-19 |
2005-09-01 |
Genentech, Inc. |
Cdr-repaired antibodies
|
|
TW200539855A
(en)
*
|
2004-03-15 |
2005-12-16 |
Wyeth Corp |
Calicheamicin conjugates
|
|
US7276585B2
(en)
*
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
JP2007532680A
(ja)
*
|
2004-04-16 |
2007-11-15 |
ジェネンテック・インコーポレーテッド |
疾患の治療方法
|
|
BRPI0510915A
(pt)
|
2004-06-04 |
2007-11-13 |
Genentech Inc |
método para o tratamento da esclerose múltipla e artigo manufaturado
|
|
PL1674111T3
(pl)
*
|
2004-07-09 |
2011-04-29 |
Chugai Pharmaceutical Co Ltd |
Przeciwciała anty-glipikan 3
|
|
WO2006005367A1
(en)
*
|
2004-07-14 |
2006-01-19 |
Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag |
N-glycosylated antibody
|
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
|
WO2006031994A2
(en)
*
|
2004-09-14 |
2006-03-23 |
Xencor, Inc. |
Monomeric immunoglobulin fc domains
|
|
ZA200702335B
(en)
|
2004-10-05 |
2009-05-27 |
Genentech Inc |
Method for treating vasculitis
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
JP4794457B2
(ja)
*
|
2004-10-26 |
2011-10-19 |
中外製薬株式会社 |
糖鎖改変抗グリピカン３抗体
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
DK1817340T3
(da)
|
2004-11-12 |
2012-08-13 |
Xencor Inc |
Fc-varianter med ændret binding til fcrn
|
|
US20060275282A1
(en)
*
|
2005-01-12 |
2006-12-07 |
Xencor, Inc. |
Antibodies and Fc fusion proteins with altered immunogenicity
|
|
UA94899C2
(ru)
|
2005-01-21 |
2011-06-25 |
Дженентек, Инк. |
Фиксированное дозирование антител к her
|
|
BRPI0607315B1
(pt)
|
2005-02-07 |
2022-05-17 |
Roche Glycart Ag |
Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
|
|
BRPI0607203A2
(pt)
*
|
2005-02-18 |
2009-08-25 |
Medarex Inc |
anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
|
|
DK1850874T3
(da)
|
2005-02-23 |
2013-11-11 |
Genentech Inc |
Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
|
|
KR20070114324A
(ko)
*
|
2005-03-25 |
2007-11-30 |
글리카트 바이오테크놀로지 아게 |
Ｍｃｓｐ 에 향하며 증가된 ｆｃ 수용체 결합 친화도 및효과기 작용을 갖는 항원 결합 분자
|
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
|
WO2007039818A2
(en)
*
|
2005-05-09 |
2007-04-12 |
Glycart Biotechnology Ag |
Antigen binding molecules having modified fc regions and altered binding to fc receptors
|
|
US20070014720A1
(en)
*
|
2005-06-02 |
2007-01-18 |
Gadi Gazit-Bornstein |
Antibodies directed to CD20 and uses thereof
|
|
EP1888638A2
(en)
*
|
2005-06-03 |
2008-02-20 |
Genentech, Inc. |
Method of producing antibodies with modified fucosylation level
|
|
PT2452694T
(pt)
|
2005-06-30 |
2019-02-21 |
Janssen Biotech Inc |
Anticorpos anti-il-23, composições, métodos e utilizações
|
|
AU2006272204A1
(en)
|
2005-07-21 |
2007-01-25 |
Genmab A/S |
Potency assays for antibody drug substance binding to an Fc receptor
|
|
JP2009526746A
(ja)
*
|
2005-08-19 |
2009-07-23 |
セントカー・インコーポレーテツド |
タンパク質分解抵抗性の抗体調製物
|
|
TWI478940B
(zh)
*
|
2005-08-26 |
2015-04-01 |
Roche Glycart Ag |
具有經改變細胞傳訊活性之改質抗原結合分子
|
|
AU2006299429B2
(en)
*
|
2005-10-03 |
2012-02-23 |
Xencor, Inc. |
Fc variants with optimized Fc receptor binding properties
|
|
US7973136B2
(en)
*
|
2005-10-06 |
2011-07-05 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
US20070087005A1
(en)
*
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
WO2007126439A2
(en)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
|
EA035459B1
(ru)
|
2005-12-29 |
2020-06-19 |
Сентокор, Инк. |
Антитело против il-23p19
|
|
SI1973950T1
(sl)
|
2006-01-05 |
2015-01-30 |
Genentech, Inc. |
Anti-EphB4 protitelesa in postopki njihove uporabe
|
|
US20070166306A1
(en)
*
|
2006-01-17 |
2007-07-19 |
Fey Georg H M |
Anti-CD19 antibody composition and method
|
|
MX2008009220A
(es)
|
2006-01-17 |
2008-10-10 |
Biolex Therapeutics Inc |
Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
|
|
EP1987068B1
(en)
*
|
2006-02-10 |
2018-08-08 |
Life Technologies Corporation |
Oligosaccharide modification and labeling of proteins
|
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
|
JP2009531324A
(ja)
|
2006-03-20 |
2009-09-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
|
|
CL2007001536A1
(es)
|
2006-05-30 |
2008-01-25 |
Genentech Inc |
Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
|
|
CA2654000A1
(en)
|
2006-06-06 |
2008-05-22 |
Genentech, Inc. |
Anti-dll4 antibodies and methods using same
|
|
PL2468770T3
(pl)
|
2006-07-14 |
2018-07-31 |
Ac Immune S.A. |
Humanizowane przeciwciało przeciw amyloidowi beta
|
|
SI2468770T1
(en)
|
2006-07-14 |
2018-05-31 |
Ac Immune S.A. |
A humanized antibody against amyloid beta.
|
|
WO2008011081A2
(en)
|
2006-07-19 |
2008-01-24 |
The Trustees Of The University Of Pennsylvania |
Wsx-1/p28 as a target for anti-inflammatory responses
|
|
AR062223A1
(es)
*
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
JP5825756B2
(ja)
*
|
2006-08-14 |
2015-12-02 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ１９を標的とする最適化抗体
|
|
BRPI0716762A2
(pt)
|
2006-09-13 |
2013-09-24 |
Abbott Lab |
melhorias da cultura celular
|
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
|
EP2084188A2
(en)
|
2006-10-12 |
2009-08-05 |
Genentech, Inc. |
Antibodies to lymphotoxin-alpha
|
|
EP2061814B1
(en)
|
2006-10-27 |
2012-06-06 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
BRPI0717902A2
(pt)
*
|
2006-12-01 |
2013-10-29 |
Medarex Inc |
"anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
|
|
KR20090114443A
(ko)
|
2007-02-09 |
2009-11-03 |
제넨테크, 인크. |
항-Ｒｏｂｏ４ 항체 및 그의 용도
|
|
BRPI0808418A2
(pt)
|
2007-03-02 |
2014-07-22 |
Genentech, Inc |
Predição de resposta a um inibidor de her
|
|
RU2479629C2
(ru)
*
|
2007-03-07 |
2013-04-20 |
Гликофи, Инк. |
Продукция гликопротеинов с модифицированным фукозилированием
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
AU2008237632B2
(en)
|
2007-04-17 |
2014-01-16 |
Stichting Dienst Landbouwkundig Onderzoek |
Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases
|
|
HUE026728T2
(en)
|
2007-05-14 |
2016-06-28 |
Medimmune Llc |
A method for reducing eosinophil levels
|
|
ES2583377T3
(es)
|
2007-06-08 |
2016-09-20 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
|
NZ599497A
(en)
|
2007-06-12 |
2013-11-29 |
Ac Immune Sa |
Humanized antibodies to amyloid beta
|
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
|
CN101918559A
(zh)
*
|
2007-06-15 |
2010-12-15 |
麦迪卡格公司 |
修饰植物中的糖蛋白产生
|
|
MX354993B
(es)
|
2007-07-09 |
2018-03-28 |
Genentech Inc |
Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
|
|
WO2009032949A2
(en)
|
2007-09-04 |
2009-03-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
|
DK3059246T3
(en)
|
2007-09-26 |
2018-10-01 |
Chugai Pharmaceutical Co Ltd |
Modified constant region of an antibody
|
|
EP2650308A3
(en)
|
2007-10-05 |
2014-11-12 |
Genentech, Inc. |
Use of anti-amyloid beta antibody in ocular diseases
|
|
NO2514436T3
(enExample)
|
2007-11-07 |
2018-05-19 |
|
|
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
|
AU2008342956A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Genentech, Inc. |
Therapy of rituximab-refractory rheumatoid arthritis patients
|
|
DK2242772T3
(en)
*
|
2007-12-26 |
2015-01-05 |
Biotest Ag |
Immunoconjugates that targets CD138, and uses thereof
|
|
WO2009080831A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
|
PL2808343T3
(pl)
|
2007-12-26 |
2019-11-29 |
Xencor Inc |
Warianty Fc ze zmienionym wiązaniem do FcRn
|
|
BRPI0821447A2
(pt)
*
|
2007-12-26 |
2015-06-16 |
Biotest Ag |
Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
|
|
CN101945892B
(zh)
*
|
2007-12-26 |
2017-11-24 |
生物测试股份公司 |
用于改进对表达cd138的肿瘤细胞的靶向的方法和试剂
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
WO2009134738A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
|
KR101054362B1
(ko)
*
|
2008-07-03 |
2011-08-05 |
재단법인 목암생명공학연구소 |
재조합 단백질의 푸코스 함량을 감소시키는 방법
|
|
EP2318832B1
(en)
|
2008-07-15 |
2013-10-09 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
建南德克公司 |
治療進展型多發性硬化症之方法
|
|
WO2010036443A1
(en)
*
|
2008-09-26 |
2010-04-01 |
Eureka Therapeutics, Inc. |
Cell lines and proteins with variant glycosylation pattern
|
|
EP3524620A1
(en)
|
2008-10-14 |
2019-08-14 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
TW201028433A
(en)
|
2008-10-20 |
2010-08-01 |
Abbott Lab |
Viral inactivation during purification of antibodies
|
|
TWI610936B
(zh)
*
|
2008-10-20 |
2018-01-11 |
艾伯維有限公司 |
使用蛋白質ａ親和性層析進行抗體之分離及純化
|
|
AR074203A1
(es)
|
2008-11-22 |
2010-12-29 |
Genentech Inc |
Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.
|
|
UY32341A
(es)
|
2008-12-19 |
2010-07-30 |
Glaxo Group Ltd |
Proteínas de unión antígeno novedosas
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
BRPI0918204A2
(pt)
|
2008-12-23 |
2015-12-08 |
Genentech Inc |
igv variante composição farmaceutica e kit
|
|
WO2010096486A1
(en)
|
2009-02-17 |
2010-08-26 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
|
WO2010098865A1
(en)
*
|
2009-02-26 |
2010-09-02 |
Gt Life Sciences, Inc. |
Mammalian cell line models and related methods
|
|
NZ594665A
(en)
|
2009-03-20 |
2013-08-30 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
EP3702371B1
(en)
|
2009-03-25 |
2022-11-02 |
Genentech, Inc. |
Anti-fgfr3 antibodies and methods using same
|
|
AU2010229479B2
(en)
|
2009-03-25 |
2013-03-28 |
Genentech, Inc. |
Novel anti-alpha5beta1 antibodies and uses thereof
|
|
CN102369214B
(zh)
|
2009-04-07 |
2019-04-12 |
罗氏格黎卡特股份公司 |
三价、双特异性抗体
|
|
SG10201401976YA
(en)
*
|
2009-05-06 |
2014-10-30 |
Biotest Ag |
Uses of immunoconjugates targeting cd138
|
|
US8815242B2
(en)
|
2009-05-27 |
2014-08-26 |
Synageva Biopharma Corp. |
Avian derived antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
|
AR077595A1
(es)
|
2009-07-27 |
2011-09-07 |
Genentech Inc |
Tratamientos de combinacion
|
|
WO2011014750A1
(en)
|
2009-07-31 |
2011-02-03 |
Genentech, Inc. |
Inhibition of tumor metastasis using bv8- or g-csf-antagonists
|
|
BR112012002974B1
(pt)
|
2009-08-11 |
2022-06-07 |
Genentech, Inc |
Processo para produzir um anticorpo em uma célula hospedeira de célula ovário de hamster chinês (cho) expressando o referido polipeptídeo
|
|
BR112012003346A2
(pt)
|
2009-08-15 |
2016-11-16 |
Genentech Inc |
metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial
|
|
TWI412375B
(zh)
*
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗ｃｄｃｐ１抗體
|
|
RU2570554C2
(ru)
|
2009-08-31 |
2015-12-10 |
Роше Гликарт Аг |
Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
|
|
EP2473522B1
(en)
|
2009-09-02 |
2016-08-17 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
JP5814925B2
(ja)
|
2009-10-22 |
2015-11-17 |
ジェネンテック， インコーポレイテッド |
抗ヘプシン抗体及びその使用方法
|
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
|
EP2496600A1
(en)
|
2009-11-04 |
2012-09-12 |
Fabrus LLC |
Methods for affinity maturation-based antibody optimization
|
|
CN105274170A
(zh)
|
2009-11-05 |
2016-01-27 |
弗·哈夫曼-拉罗切有限公司 |
分泌异源多肽的方法和组合物
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
EP2506876B1
(en)
|
2009-12-02 |
2016-10-12 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
EP2509626B1
(en)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c antibodies and methods using same
|
|
JP5852010B2
(ja)
|
2009-12-23 |
2016-02-03 |
ジェネンテック， インコーポレイテッド |
抗Ｂｖ８抗体およびその使用
|
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
|
US8940303B2
(en)
|
2010-01-28 |
2015-01-27 |
Glaxo Group Limited |
CD127 binding proteins
|
|
EA201290630A1
(ru)
|
2010-02-09 |
2013-03-29 |
Глаксо Груп Лимитед |
Лечение расстройства обмена веществ
|
|
WO2011100403A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc |
Cd20 antibodies and uses thereof
|
|
US20110200595A1
(en)
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
|
MX2012008958A
(es)
|
2010-02-18 |
2012-08-23 |
Genentech Inc |
Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
|
|
CN110227154A
(zh)
|
2010-02-23 |
2019-09-13 |
霍夫曼-拉罗奇有限公司 |
用于治疗卵巢癌的抗血管发生疗法
|
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
|
MX2012010853A
(es)
|
2010-03-24 |
2013-01-29 |
Genentech Inc |
Anticuerpos anti-lrp6.
|
|
EP2374816B1
(en)
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
|
US9441032B2
(en)
|
2010-04-07 |
2016-09-13 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
CN103068378B
(zh)
|
2010-05-10 |
2016-07-06 |
中央研究院 |
具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
|
UY33421A
(es)
|
2010-06-03 |
2011-12-30 |
Glaxo Wellcome House |
Proteinas de union al antígeno humanizados
|
|
NZ701208A
(en)
|
2010-06-03 |
2016-05-27 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
|
|
WO2011159980A1
(en)
|
2010-06-18 |
2011-12-22 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
JP2013539962A
(ja)
|
2010-07-09 |
2013-10-31 |
ジェネンテック， インコーポレイテッド |
抗ニューロピリン抗体及び使用方法
|
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
|
EP2409989A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Method to improve glycosylation profile for antibody
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
WO2012012750A1
(en)
|
2010-07-23 |
2012-01-26 |
Trustees Of Boston University |
ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
|
|
JP2013541501A
(ja)
|
2010-08-03 |
2013-11-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
慢性リンパ性白血病（ｃｌｌ）のバイオマーカー
|
|
BR112013002532A2
(pt)
|
2010-08-05 |
2016-05-31 |
Hoffmann La Roche |
proteína de fusão de citocina anti-viral do anticorpo anti-mhc
|
|
KR101653030B1
(ko)
|
2010-08-13 |
2016-08-31 |
로슈 글리카트 아게 |
항-테나신-c a２ 항체 및 이의 사용 방법
|
|
SG187746A1
(en)
|
2010-08-13 |
2013-03-28 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
|
TW201215405A
(en)
|
2010-08-25 |
2012-04-16 |
Hoffmann La Roche |
Antibodies against IL-18R1 and uses thereof
|
|
CA2808236A1
(en)
|
2010-08-31 |
2012-03-08 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
|
EP2625197B1
(en)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
EP2638067A2
(en)
|
2010-11-08 |
2013-09-18 |
Genentech, Inc. |
Subcutaneously administered anti-il-6 receptor antibody
|
|
AR083819A1
(es)
|
2010-11-10 |
2013-03-27 |
Genentech Inc |
UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
|
|
WO2012069433A2
(en)
|
2010-11-23 |
2012-05-31 |
Glaxo Group Limited |
Antigen binding proteins
|
|
JP2014501725A
(ja)
|
2010-11-24 |
2014-01-23 |
グラクソ グループ リミテッド |
Ｈｇｆを標的とする多特異的抗原結合タンパク質
|
|
CN110251668A
(zh)
|
2010-11-30 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
低亲和力血脑屏障受体抗体及其用途
|
|
JP6005657B2
(ja)
|
2010-12-16 |
2016-10-12 |
ジェネンテック， インコーポレイテッド |
Ｔｈ２阻害に関連する診断及び治療
|
|
WO2012087962A2
(en)
|
2010-12-20 |
2012-06-28 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
CA2820953A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
EP2482074A1
(en)
*
|
2011-01-27 |
2012-08-01 |
Medizinische Hochschule Hannover |
Methods and means for diagnosing vasculitis
|
|
EP2672999A2
(en)
|
2011-02-10 |
2013-12-18 |
Roche Glycart AG |
Improved immunotherapy
|
|
US9266938B2
(en)
|
2011-02-10 |
2016-02-23 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
JP5764677B2
(ja)
|
2011-02-28 |
2015-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合タンパク質
|
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
|
BR112013021460B1
(pt)
|
2011-03-02 |
2022-12-20 |
Roche Glycart Ag |
Anticorpos, composição e uso do anticorpo
|
|
MX342240B
(es)
|
2011-04-07 |
2016-09-21 |
Genentech Inc |
Anticuerpos anti-fgfr4 y metodos de uso.
|
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
|
MX2013013054A
(es)
|
2011-05-12 |
2014-02-20 |
Genentech Inc |
Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
|
|
PE20140995A1
(es)
|
2011-05-16 |
2014-08-23 |
Genentech Inc |
Agonistas de fgfr1 y sus metodos de uso
|
|
SG194176A1
(en)
|
2011-05-27 |
2013-12-30 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
KR101629073B1
(ko)
|
2011-06-15 |
2016-06-09 |
에프. 호프만-라 로슈 아게 |
항-인간 에리스로포이에틴 수용체 항체 및 이의 사용 방법
|
|
KR102038155B1
(ko)
|
2011-06-22 |
2019-10-29 |
에프. 호프만-라 로슈 아게 |
Mhc 클래스 i 포함 복합체를 사용한 순환 바이러스-특이적 세포독성 t-세포에 의한 표적 세포의 제거
|
|
BR112013030472A2
(pt)
|
2011-06-30 |
2019-09-24 |
Genentech Inc |
formulação farmacêutica, artigo de fabricação e método
|
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
|
CN103842380A
(zh)
|
2011-07-27 |
2014-06-04 |
葛兰素集团有限公司 |
融合至Fc结构域的抗VEGF单可变结构域
|
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
|
WO2013026832A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
|
HRP20181355T1
(hr)
|
2011-08-23 |
2018-10-19 |
Roche Glycart Ag |
Bispecifične molekule koje se vežu na antigen
|
|
BR112014005720A2
(pt)
|
2011-09-15 |
2017-12-12 |
Genentech Inc |
método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
|
|
US20130078252A1
(en)
|
2011-09-19 |
2013-03-28 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
|
US9663573B2
(en)
|
2011-10-05 |
2017-05-30 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
|
JP6532678B2
(ja)
|
2011-10-14 |
2019-06-19 |
ジェネンテック， インコーポレイテッド |
抗ＨｔｒＡ１抗体及び使用方法
|
|
CA2851053A1
(en)
|
2011-10-19 |
2013-04-25 |
Roche Glycart Ag |
Separation method for fucosylated antibodies
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
|
CA2850034A1
(en)
|
2011-10-28 |
2013-05-02 |
Genentech, Inc. |
Therapeutic combinations and methods of treating melanoma
|
|
TW201326193A
(zh)
|
2011-11-21 |
2013-07-01 |
Genentech Inc |
抗－ｃ－ｍｅｔ抗體之純化
|
|
US20140335084A1
(en)
|
2011-12-06 |
2014-11-13 |
Hoffmann-La Roche Inc. |
Antibody formulation
|
|
CN104302324A
(zh)
|
2011-12-08 |
2015-01-21 |
生物测试股份公司 |
靶向cd138的免疫偶联物的用途
|
|
HK1200849A1
(en)
|
2011-12-22 |
2015-08-14 |
F. Hoffmann-La Roche Ag |
Full length antibody display system for eukaryotic cells and its use
|
|
CN104114701A
(zh)
|
2011-12-22 |
2014-10-22 |
弗·哈夫曼-拉罗切有限公司 |
表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
|
|
CN113896787A
(zh)
|
2011-12-22 |
2022-01-07 |
弗·哈夫曼-拉罗切有限公司 |
表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
|
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
|
WO2013106489A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
|
CA2862422A1
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Anti-lrp5 antibodies and methods of use
|
|
JP2015506944A
(ja)
|
2012-01-18 |
2015-03-05 |
ジェネンテック， インコーポレイテッド |
Ｆｇｆ１９修飾薬を使用する方法
|
|
WO2013113641A1
(en)
|
2012-01-31 |
2013-08-08 |
Roche Glycart Ag |
Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
|
|
MX366804B
(es)
|
2012-02-11 |
2019-07-25 |
Genentech Inc |
Translocaciones de la r-espondina y sus metodos de uso.
|
|
SI2814587T1
(en)
|
2012-02-15 |
2018-08-31 |
F. Hoffmann-La Roche Ag |
Affinity chromatography based on the Fc receptor
|
|
KR20140130455A
(ko)
|
2012-03-02 |
2014-11-10 |
로슈 글리카트 아게 |
Adcc-강화 항체를 사용한 암 치료용 예측 바이오마커
|
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
|
US9505833B2
(en)
|
2012-04-20 |
2016-11-29 |
Abbvie Inc. |
Human antibodies that bind human TNF-alpha and methods of preparing the same
|
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
JP6242865B2
(ja)
|
2012-05-01 |
2017-12-06 |
ジェネンテック， インコーポレイテッド |
抗ｐｍｅｌ１７抗体および免疫複合体
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
AU2013262611B2
(en)
|
2012-05-18 |
2018-03-01 |
Genentech, Inc. |
High-concentration monoclonal antibody formulations
|
|
AU2013266611B2
(en)
|
2012-05-21 |
2016-08-11 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
|
WO2013177470A1
(en)
|
2012-05-23 |
2013-11-28 |
Genentech, Inc. |
Selection method for therapeutic agents
|
|
US9695454B2
(en)
|
2012-05-23 |
2017-07-04 |
Glykos Finland Oy |
Production of fucosylated glycoproteins
|
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
|
CN103463633B
(zh)
*
|
2012-06-07 |
2016-03-30 |
复旦大学 |
一种靶向的嵌合乙肝核心抗原治疗性疫苗及其用途
|
|
JP2015530867A
(ja)
|
2012-06-15 |
2015-10-29 |
ジェネンテック， インコーポレイテッド |
抗ｐｃｓｋ９抗体、製剤、投薬、及び使用方法
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
CA2872184A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-theophylline antibodies and methods of use
|
|
SI2869848T1
(sl)
|
2012-07-04 |
2017-01-31 |
F. Hoffmann-La Roche Ag |
Kovalentno vezani konjugati antigen-protitelo
|
|
RU2630296C2
(ru)
|
2012-07-04 |
2017-09-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к биотину и способы их применения
|
|
SI2870247T1
(sl)
|
2012-07-05 |
2019-10-30 |
Hoffmann La Roche |
Ekspresijski in sekrecijski sistem
|
|
SG11201500142RA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd22 antibodies
|
|
WO2014011521A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti - cd79b antibodies
|
|
IN2014DN10652A
(enExample)
|
2012-07-09 |
2015-09-11 |
Genentech Inc |
|
|
TW201406785A
(zh)
|
2012-07-09 |
2014-02-16 |
Genentech Inc |
抗ｃｄ２２抗體及免疫結合物
|
|
EP2872534B1
(en)
|
2012-07-13 |
2018-08-08 |
Roche Glycart AG |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
RU2681730C2
(ru)
|
2012-07-25 |
2019-03-12 |
Селлдекс Терапьютикс Инк. |
Антитела против kit и их применения
|
|
CN104662045B
(zh)
|
2012-08-07 |
2019-04-05 |
罗切格利卡特公司 |
包含两种工程化改造成具有降低的和升高的效应器功能的抗体的组合物改进的免疫疗法
|
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
|
US9547009B2
(en)
|
2012-08-21 |
2017-01-17 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
|
EP2888279A1
(en)
|
2012-08-22 |
2015-07-01 |
Glaxo Group Limited |
Anti lrp6 antibodies
|
|
KR20190121874A
(ko)
|
2012-08-29 |
2019-10-28 |
에프. 호프만-라 로슈 아게 |
혈액 뇌 장벽 셔틀
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
HK1211981A1
(en)
|
2012-09-02 |
2016-06-03 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
|
CN104768581A
(zh)
|
2012-09-07 |
2015-07-08 |
吉宁特有限公司 |
II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
|
|
KR101645905B1
(ko)
|
2012-10-12 |
2016-08-04 |
스피로즌 살 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
|
US10100102B2
(en)
|
2012-10-29 |
2018-10-16 |
The University Of North Carolina At Chapel Hill |
Compositions and methods for inhibiting pathogen infection
|
|
HK1214831A1
(zh)
|
2012-11-05 |
2016-08-05 |
Foundation Medicine, Inc. |
新型融合分子及其应用
|
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
|
EP2917243B1
(en)
|
2012-11-08 |
2018-03-14 |
F.Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
|
AU2013345072B2
(en)
|
2012-11-13 |
2017-12-07 |
Genentech, Inc. |
Anti-hemagglutinin antibodies and methods of use
|
|
SG11201504414UA
(en)
|
2012-12-21 |
2015-07-30 |
Hoffmann La Roche |
Disulfide-linked multivalent mhc class i comprising multi-function proteins
|
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014114595A1
(en)
|
2013-01-23 |
2014-07-31 |
Roche Glycart Ag |
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
CN105308068A
(zh)
|
2013-02-13 |
2016-02-03 |
法国化学与生物科技实验室 |
高度半乳糖基化的抗TNF-α抗体及其用途
|
|
BR112015019348A2
(pt)
|
2013-02-13 |
2017-08-22 |
Lab Francais Du Fractionnement |
Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
|
|
EP2958592A1
(en)
|
2013-02-22 |
2015-12-30 |
F. Hoffmann-La Roche AG |
Methods of treating cancer and preventing drug resistance
|
|
KR20150123811A
(ko)
|
2013-02-26 |
2015-11-04 |
로슈 글리카트 아게 |
항-mcsp 항체
|
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
|
EP2968585B1
(en)
|
2013-03-13 |
2018-07-18 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
|
BR112015022576A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
EA201591750A1
(ru)
|
2013-03-14 |
2016-05-31 |
Дженентек, Инк. |
Антитела против b7-h4 и иммуноконъюгаты
|
|
HK1220916A1
(zh)
|
2013-03-14 |
2017-05-19 |
基因泰克公司 |
治疗癌症和预防癌症药物抗性的方法
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
CN105339001A
(zh)
|
2013-03-15 |
2016-02-17 |
基因泰克公司 |
治疗癌症和预防癌症耐药性的方法
|
|
KR20250091304A
(ko)
|
2013-03-15 |
2025-06-20 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
|
US20140328849A1
(en)
|
2013-03-15 |
2014-11-06 |
Genentech, Inc. |
Anti-crth2 antibodies and methods of use
|
|
US9550829B2
(en)
|
2013-03-15 |
2017-01-24 |
Genentech, Inc. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
HRP20201113T1
(hr)
|
2013-03-15 |
2020-10-30 |
Glaxosmithkline Intellectual Property Development Limited |
Vežući proteini protiv lag-3
|
|
EP2970422B1
(en)
|
2013-03-15 |
2018-04-18 |
F.Hoffmann-La Roche Ag |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
|
US9598485B2
(en)
|
2013-03-15 |
2017-03-21 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
US20160068613A1
(en)
|
2013-04-29 |
2016-03-10 |
Hoffmann-La Roche Inc. |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
|
EP3628685A1
(en)
|
2013-04-29 |
2020-04-01 |
F. Hoffmann-La Roche AG |
Human fcrn-binding modified antibodies and methods of use
|
|
SG10201810481UA
(en)
|
2013-04-29 |
2018-12-28 |
Hoffmann La Roche |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
PH12019501393B1
(en)
|
2013-08-01 |
2022-09-07 |
Five Prime Therapeutics Inc |
Afucosylated anti-fgfr2iiib antibodies
|
|
CA2920666A1
(en)
|
2013-08-12 |
2015-02-19 |
Genentech, Inc. |
Compositions and method for treating complement-associated conditions
|
|
CA2923579C
(en)
|
2013-09-06 |
2023-09-05 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
|
AR097685A1
(es)
|
2013-09-17 |
2016-04-06 |
Genentech Inc |
Métodos de uso de anticuerpos anti-lgr5
|
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
|
JP2016537965A
(ja)
|
2013-10-11 |
2016-12-08 |
ジェネンテック， インコーポレイテッド |
Ｎｓｐ４阻害剤及び使用方法
|
|
CA2925393C
(en)
|
2013-10-11 |
2023-03-07 |
Dimiter Dimitrov |
Tem8 antibodies and their use
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
CN105744954B
(zh)
|
2013-10-18 |
2021-03-05 |
豪夫迈·罗氏有限公司 |
抗rspo2和/或抗rspo3抗体及其用途
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
BR112016008694A2
(pt)
|
2013-10-23 |
2017-10-03 |
Genentech Inc |
Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
|
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
WO2015075011A1
(en)
|
2013-11-21 |
2015-05-28 |
F. Hoffmann-La Roche Ag |
ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
|
|
SG11201604632PA
(en)
|
2013-12-09 |
2016-07-28 |
Allakos Inc |
Anti-siglec-8 antibodies and methods of use thereof
|
|
JP2017505756A
(ja)
|
2013-12-13 |
2017-02-23 |
ザ ジェネラル ホスピタル コーポレイション |
可溶性高分子量（ｈｍｗ）タウ種およびその用途
|
|
MX2016007576A
(es)
|
2013-12-13 |
2016-10-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33.
|
|
NZ760065A
(en)
|
2013-12-17 |
2022-12-23 |
Genentech Inc |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
MX2016007885A
(es)
|
2013-12-17 |
2017-01-11 |
Genentech Inc |
Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
|
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
KR102225489B1
(ko)
|
2013-12-17 |
2021-03-10 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
|
PL3087095T3
(pl)
|
2013-12-24 |
2020-03-31 |
Argenx Bvba |
Antagoniści fcrn i sposoby stosowania
|
|
ES2895752T3
(es)
|
2014-01-03 |
2022-02-22 |
Hoffmann La Roche |
Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
|
|
MX373017B
(es)
|
2014-01-03 |
2020-04-28 |
Hoffmann La Roche |
Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
MX373856B
(es)
|
2014-01-03 |
2020-03-25 |
Hoffmann La Roche |
Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
|
|
CA2932547C
(en)
|
2014-01-06 |
2023-05-23 |
F. Hoffmann-La Roche Ag |
Monovalent blood brain barrier shuttle modules
|
|
WO2015107026A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
US9982041B2
(en)
|
2014-01-16 |
2018-05-29 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
KR20160111469A
(ko)
|
2014-01-24 |
2016-09-26 |
제넨테크, 인크. |
항-steap1 항체 및 면역접합체를 사용하는 방법
|
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
AU2015214058B2
(en)
|
2014-02-08 |
2020-07-09 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
|
TWI769970B
(zh)
|
2014-02-08 |
2022-07-11 |
美商建南德克公司 |
治療阿茲海默症之方法
|
|
WO2015123325A1
(en)
|
2014-02-12 |
2015-08-20 |
Genentech, Inc. |
Anti-jagged1 antibodies and methods of use
|
|
CN106029693A
(zh)
|
2014-02-21 |
2016-10-12 |
豪夫迈·罗氏有限公司 |
抗il-13/il-17双特异性抗体及其用途
|
|
JP6825909B2
(ja)
|
2014-02-28 |
2021-02-03 |
アラコス インコーポレイテッド |
シグレック−８関連疾患を処置するための方法および組成物
|
|
BR112016020822A2
(pt)
|
2014-03-14 |
2017-10-03 |
Genentech Inc |
Métodos e composições para secreção de polipeptídeos heterólogos
|
|
BR112016023417A2
(pt)
|
2014-03-21 |
2019-04-16 |
F. Hoffmann-La Roche Ag |
predição in vitro de meia-vida in vivo
|
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
HRP20192285T1
(hr)
|
2014-03-31 |
2020-03-06 |
F. Hoffmann - La Roche Ag |
Anti-ox40 protutijela i postupci uporabe
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
RU2016150370A
(ru)
|
2014-05-22 |
2018-06-26 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против GPC3
|
|
MX2016015163A
(es)
|
2014-05-23 |
2017-03-03 |
Genentech Inc |
Biomarcadores mit y metodos para su uso.
|
|
EP3904388A1
(en)
|
2014-05-27 |
2021-11-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
|
CN106661099A
(zh)
|
2014-05-27 |
2017-05-10 |
中央研究院 |
抗her2醣抗体及其用途
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
US20150344585A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
|
EP3154582A4
(en)
|
2014-05-28 |
2018-01-10 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
|
KR20170010785A
(ko)
|
2014-06-11 |
2017-02-01 |
제넨테크, 인크. |
항-lgr5 항체 및 이의 용도
|
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
|
EP3164419B1
(en)
|
2014-06-26 |
2024-07-24 |
F. Hoffmann-La Roche AG |
Anti-brdu antibodies and methods of use
|
|
BR112017000130A2
(pt)
|
2014-07-11 |
2018-01-09 |
Genentech Inc |
método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
|
|
BR112017000497B1
(pt)
|
2014-07-11 |
2023-12-26 |
Ventana Medical Systems, Inc |
Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
|
|
CN108064266A
(zh)
|
2014-07-21 |
2018-05-22 |
格利科斯芬兰公司 |
在丝状真菌中具有哺乳动物样n-聚糖的糖蛋白的制备
|
|
MY198017A
(en)
|
2014-08-19 |
2023-07-26 |
Merck Sharp & Dohme |
Anti-tigit antibodies
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
ES3034398T3
(en)
|
2014-08-28 |
2025-08-18 |
Bioatla Inc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
EP3191500A4
(en)
|
2014-09-08 |
2018-04-11 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
|
WO2016037644A1
(en)
|
2014-09-10 |
2016-03-17 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US10059768B2
(en)
|
2014-09-12 |
2018-08-28 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
AU2015314954B2
(en)
|
2014-09-12 |
2021-05-13 |
Genentech, Inc. |
Anti-HER2 antibodies and immunoconjugates
|
|
SG11201701627PA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Anti-cll-1 antibodies and immunoconjugates
|
|
WO2016044396A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック， インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
|
US10626176B2
(en)
|
2014-10-31 |
2020-04-21 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind B7-H4
|
|
CN107109484B
(zh)
|
2014-11-03 |
2021-12-14 |
豪夫迈·罗氏有限公司 |
用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
|
|
AU2015343337A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Assays for detecting T cell immune subsets and methods of use thereof
|
|
RU2017119185A
(ru)
|
2014-11-05 |
2018-12-05 |
Дженентек, Инк. |
Антитела против fgfr2/3 и способы их применения
|
|
EP3215524B1
(en)
|
2014-11-06 |
2021-01-13 |
F.Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
SI3215528T1
(sl)
|
2014-11-06 |
2019-11-29 |
Hoffmann La Roche |
Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
|
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
|
CA2960297A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
EP3217787B1
(en)
|
2014-11-10 |
2019-04-17 |
F.Hoffmann-La Roche Ag |
Animal model for nephropathy and agents for treating the same
|
|
EP3875481B1
(en)
|
2014-11-14 |
2025-01-22 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
DK3489256T3
(da)
|
2014-11-14 |
2021-05-25 |
Hoffmann La Roche |
Antigenbindende molekyler omfattende en TNF-familieligandtrimer
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
ES2848376T3
(es)
|
2014-11-19 |
2021-08-09 |
Axon Neuroscience Se |
Anticuerpos de tau humanizados en la enfermedad de Alzheimer
|
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
|
|
EP3221364B1
(en)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
RU2753902C2
(ru)
|
2014-11-20 |
2021-08-24 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
|
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
AU2015358325A1
(en)
|
2014-12-05 |
2017-05-25 |
Genentech, Inc. |
Anti-CD79b antibodies and methods of use
|
|
WO2016094566A2
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
|
TWI656133B
(zh)
|
2014-12-19 |
2019-04-11 |
日商中外製藥股份有限公司 |
抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
|
|
KR101838645B1
(ko)
|
2014-12-19 |
2018-03-14 |
추가이 세이야쿠 가부시키가이샤 |
항-c5 항체 및 그의 사용 방법
|
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
AU2016206457B2
(en)
|
2015-01-16 |
2021-11-11 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ROR1
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
JP2018511557A
(ja)
|
2015-01-22 |
2018-04-26 |
中外製薬株式会社 |
２種以上の抗ｃ５抗体の組み合わせおよび使用方法
|
|
CA2972072A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
|
EP3250927B1
(en)
|
2015-01-28 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
Gene expression markers and treatment of multiple sclerosis
|
|
US10330683B2
(en)
|
2015-02-04 |
2019-06-25 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
WO2016125495A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
KR20170140180A
(ko)
|
2015-02-24 |
2017-12-20 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
|
|
ES2882999T3
(es)
|
2015-03-09 |
2021-12-03 |
Argenx Bvba |
Métodos para reducir los niveles séricos de agentes que contienen Fc mediante el uso de antagonistas de FcRn
|
|
CA2977285A1
(en)
|
2015-03-16 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
SMT202000255T1
(it)
|
2015-03-20 |
2020-07-08 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Anticorpi neutralizzanti diretti contro gp120 e loro utilizzo
|
|
KR20170129902A
(ko)
|
2015-03-23 |
2017-11-27 |
조운스 테라퓨틱스, 인크. |
Icos에 대한 항체
|
|
CA2980390A1
(en)
|
2015-03-23 |
2016-09-29 |
Bayer Pharma Aktiengesellschaft |
Anti-ceacam6 antibodies and uses thereof
|
|
RU2021124437A
(ru)
|
2015-04-03 |
2021-09-29 |
Еурека Терапьютикс, Инк. |
Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
|
|
CN107810197B
(zh)
|
2015-04-24 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
|
HK1250997A1
(zh)
|
2015-05-01 |
2019-01-18 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
|
PH12017502013B1
(en)
|
2015-05-07 |
2022-07-22 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
|
HK1248577A1
(zh)
|
2015-05-11 |
2018-10-19 |
F. Hoffmann-La Roche Ag |
治疗狼疮性肾炎的组合物和方法
|
|
EP3294770B2
(en)
|
2015-05-12 |
2024-03-20 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
|
KR20250151554A
(ko)
|
2015-05-29 |
2025-10-21 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
MX388405B
(es)
|
2015-05-29 |
2025-03-19 |
Genentech Inc |
Un anticuerpo anti-pd-l1 para usarse en el tratamiento de cáncer en sujetos que tienen nivel medio o bajo de metilación en la región promotora pd-l1.
|
|
EP3302563A1
(en)
|
2015-05-29 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
|
EP3302552A1
(en)
|
2015-06-02 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
CN107921094B
(zh)
|
2015-06-04 |
2022-03-01 |
圣拉斐尔医院有限公司 |
Igfbp3及其用途
|
|
EA033821B1
(ru)
|
2015-06-04 |
2019-11-29 |
Ospedale San Raffaele Srl |
Применение ингибитора оси igfbp3/tmem219 для лечения диабета
|
|
UA126272C2
(uk)
|
2015-06-05 |
2022-09-14 |
Дженентек, Інк. |
Антитіло проти тау-білка та спосіб його застосування
|
|
EP3303399A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies
|
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
EP3307780A1
(en)
|
2015-06-15 |
2018-04-18 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
|
ES2957567T3
(es)
|
2015-06-16 |
2024-01-22 |
Hoffmann La Roche |
Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
|
WO2016205567A1
(en)
|
2015-06-17 |
2016-12-22 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
|
ES3043088T3
(en)
|
2015-06-17 |
2025-11-24 |
Hoffmann La Roche |
Anti-her2 antibodies and methods of use
|
|
IL256080B2
(en)
|
2015-06-17 |
2025-06-01 |
Genentech Inc |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
EP3313890A1
(en)
|
2015-06-24 |
2018-05-02 |
H. Hoffnabb-La Roche Ag |
Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
|
|
PE20221007A1
(es)
|
2015-06-24 |
2022-06-15 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad disenada
|
|
ES2878316T3
(es)
|
2015-06-29 |
2021-11-18 |
Ventana Med Syst Inc |
Materiales y procedimientos para realizar ensayos histoquímicos de pro-epirregulina y anfirregulina humanas
|
|
WO2017004091A1
(en)
|
2015-06-29 |
2017-01-05 |
Genentech, Inc. |
Type ii anti-cd20 antibody for use in organ transplantation
|
|
FR3038517B1
(fr)
|
2015-07-06 |
2020-02-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation de fragments fc modifies en immunotherapie
|
|
RU2611685C2
(ru)
*
|
2015-07-20 |
2017-02-28 |
Илья Владимирович Духовлинов |
Гуманизированное моноклональное антитело, специфичное к синдекану-1
|
|
WO2017027325A1
(en)
|
2015-08-07 |
2017-02-16 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
EP3932953A1
(en)
|
2015-08-28 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Anti-hypusine antibodies and uses thereof
|
|
RU2021133819A
(ru)
|
2015-09-02 |
2021-12-10 |
Иммутеп С.A.С. |
Анти-lag-3 антитела
|
|
WO2017050729A1
(en)
|
2015-09-22 |
2017-03-30 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
|
CN108137681B
(zh)
|
2015-09-23 |
2024-06-18 |
豪夫迈·罗氏有限公司 |
抗-vegf抗体的优化的变体
|
|
RU2757135C2
(ru)
|
2015-09-24 |
2021-10-11 |
АБВИТРО ЭлЭлСи |
Композиции антител к вич и способы их применения
|
|
KR20250021613A
(ko)
|
2015-09-25 |
2025-02-13 |
제넨테크, 인크. |
항-tigit 항체 및 이의 이용 방법
|
|
US10358497B2
(en)
|
2015-09-29 |
2019-07-23 |
Amgen Inc. |
Methods of treating cardiovascular disease with an ASGR inhibitor
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
NZ741261A
(en)
|
2015-10-02 |
2019-11-29 |
Genentech Inc |
Pyrrolobenzodiazepine antibody drug conjugates and methods of use
|
|
WO2017055542A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
|
SMT202100506T1
(it)
|
2015-10-02 |
2021-11-12 |
Hoffmann La Roche |
Anticorpi bispecifici specifici per pd1 e tim3
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
MA43017A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
|
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
|
JP2018529747A
(ja)
|
2015-10-06 |
2018-10-11 |
ジェネンテック， インコーポレイテッド |
多発性硬化症を治療するための方法
|
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
AU2016334623A1
(en)
|
2015-10-07 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies with tetravalency for a costimulatory TNF receptor
|
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
|
KR20180066236A
(ko)
|
2015-10-22 |
2018-06-18 |
조운스 테라퓨틱스, 인크. |
Icos 발현을 계측하기 위한 유전자 특질
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
MX2018005036A
(es)
|
2015-10-29 |
2018-08-01 |
Hoffmann La Roche |
Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
|
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
|
NZ741780A
(en)
|
2015-10-30 |
2019-11-29 |
Genentech Inc |
Anti-htra1 antibodies and methods of use thereof
|
|
AU2016349392B2
(en)
|
2015-11-03 |
2023-07-13 |
The Trustees Of Columbia University In The City Of New York |
Neutralizing antibodies to HIV-1 gp41 and their use
|
|
CN108602884B
(zh)
|
2015-11-08 |
2024-06-25 |
豪夫迈·罗氏有限公司 |
筛选多特异性抗体的方法
|
|
JP7349787B2
(ja)
|
2015-11-23 |
2023-09-25 |
ファイヴ プライム セラピューティクス インク |
癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
|
|
ES2901794T3
(es)
|
2015-12-09 |
2022-03-23 |
Hoffmann La Roche |
Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
|
|
KR102467124B1
(ko)
|
2015-12-18 |
2022-11-15 |
추가이 세이야쿠 가부시키가이샤 |
항-c5 항체 및 사용 방법
|
|
AR107078A1
(es)
|
2015-12-18 |
2018-03-21 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
|
|
IL299759A
(en)
|
2015-12-30 |
2023-03-01 |
Genentech Inc |
Formulations with reduced polysorbate dissolution
|
|
AR107303A1
(es)
|
2016-01-08 |
2018-04-18 |
Hoffmann La Roche |
Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
|
|
CA3011739A1
(en)
|
2016-01-20 |
2017-07-27 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
|
WO2017132298A1
(en)
*
|
2016-01-27 |
2017-08-03 |
Medimmune, Llc |
Methods for preparing antibodies with a defined glycosylation pattern
|
|
EP3411396A1
(en)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
|
US10654930B2
(en)
|
2016-02-25 |
2020-05-19 |
B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University |
Composition and method for treating amyotrophic lateral sclerosis
|
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
KR20180114210A
(ko)
|
2016-03-08 |
2018-10-17 |
아카데미아 시니카 |
N-글리칸의 모듈 합성 방법 및 그의 어레이
|
|
MX2018010546A
(es)
|
2016-03-15 |
2019-02-20 |
Chugai Pharmaceutical Co Ltd |
Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
|
|
EP3433621A1
(en)
|
2016-03-25 |
2019-01-30 |
H. Hoffnabb-La Roche Ag |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
|
MA44510A
(fr)
|
2016-03-29 |
2021-03-31 |
Janssen Biotech Inc |
Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23
|
|
US20190119387A1
(en)
|
2016-04-05 |
2019-04-25 |
Glaxosmithkline Intellectual Property Development Limited |
Inhibition of tgfbeta in immunotherapy
|
|
EP3443004A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3 antibodies and methods of use
|
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
|
KR102606938B1
(ko)
|
2016-04-15 |
2023-11-29 |
바이오아트라, 인코퍼레이티드 |
항 Axl항체 및 이의 면역접합체와 이것들의 용도
|
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
CA3019524A1
(en)
|
2016-05-02 |
2017-11-09 |
F. Hoffmann-La Roche Ag |
The contorsbody - a single chain target binder
|
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
|
JP7285076B2
(ja)
|
2016-05-11 |
2023-06-01 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｔｎｆファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子
|
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
|
WO2017194441A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Modified anti-tenascin antibodies and methods of use
|
|
EP3455261B1
(en)
|
2016-05-13 |
2022-08-03 |
BioAtla, Inc. |
Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
CN118436801A
(zh)
|
2016-05-20 |
2024-08-06 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
|
CA3059010A1
(en)
|
2016-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
KR102306744B1
(ko)
|
2016-06-17 |
2021-09-28 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체 및 사용 방법
|
|
CN109563160B
(zh)
|
2016-06-24 |
2023-02-28 |
豪夫迈·罗氏有限公司 |
抗聚泛素多特异性抗体
|
|
EP3478717B1
(en)
|
2016-07-04 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Novel antibody format
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
AU2017303205B2
(en)
|
2016-07-29 |
2024-08-01 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity
|
|
MA45784A
(fr)
|
2016-07-29 |
2019-06-05 |
Juno Therapeutics Inc |
Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
|
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
CN109689099B
(zh)
|
2016-08-05 |
2023-02-28 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
|
US10538592B2
(en)
|
2016-08-22 |
2020-01-21 |
Cho Pharma, Inc. |
Antibodies, binding fragments, and methods of use
|
|
US10870694B2
(en)
|
2016-09-02 |
2020-12-22 |
Dana Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
|
US11168148B2
(en)
|
2016-09-07 |
2021-11-09 |
The Regents Of The University Of California |
Antibodies to oxidation-specific epitopes
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
WO2018050878A1
(en)
|
2016-09-19 |
2018-03-22 |
F. Hoffmann-La Roche Ag |
Complement factor based affinity chromatography
|
|
CA3031589C
(en)
|
2016-09-23 |
2025-05-06 |
Genentech, Inc. |
USES OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS
|
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
|
DK3519049T3
(da)
|
2016-09-30 |
2026-01-12 |
Janssen Biotech Inc |
Sikker og effektiv fremgangsmåde til behandling af psoriasis med specifikt anti-il23-antistof
|
|
MA46354A
(fr)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics Inc |
Molécules se liant spécifiquement au vph
|
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
IL265759B2
(en)
|
2016-10-06 |
2025-10-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
JP2019534882A
(ja)
|
2016-10-11 |
2019-12-05 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
免疫介在性療法薬を有する抗体−薬物コンジュゲート
|
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｍｉｃ抗体及び使用方法
|
|
HRP20211703T1
(hr)
|
2016-11-02 |
2022-02-04 |
Jounce Therapeutics, Inc. |
Protutijela protiv pd-1 i njihova upotreba
|
|
US11466094B2
(en)
|
2016-11-15 |
2022-10-11 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
KR20240065333A
(ko)
|
2016-11-16 |
2024-05-14 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 건선을 치료하는 방법
|
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
|
WO2018091724A1
(en)
|
2016-11-21 |
2018-05-24 |
Cureab Gmbh |
Anti-gp73 antibodies and immunoconjugates
|
|
US10759855B2
(en)
|
2016-12-02 |
2020-09-01 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to TIGIT
|
|
CN118634323A
(zh)
|
2016-12-07 |
2024-09-13 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
MX2019006334A
(es)
|
2016-12-07 |
2019-08-01 |
Genentech Inc |
Anticuerpos antitau y métodos de uso.
|
|
CA3045294A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
CN110366562A
(zh)
|
2016-12-12 |
2019-10-22 |
豪夫迈·罗氏有限公司 |
使用抗pd-l1抗体和抗雄激素治疗癌症的方法
|
|
IL267284B2
(en)
|
2016-12-19 |
2023-03-01 |
Hoffmann La Roche |
Combination therapy with a targeted 4-bb1 agonist (cd137)
|
|
KR102692708B1
(ko)
|
2016-12-20 |
2024-08-07 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
|
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
|
EP3565843A1
(en)
|
2017-01-03 |
2019-11-13 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
|
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
|
US11274157B2
(en)
|
2017-01-12 |
2022-03-15 |
Eureka Therapeutics, Inc. |
Constructs targeting histone H3 peptide/MHC complexes and uses thereof
|
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
CN110494453B
(zh)
|
2017-02-10 |
2023-05-26 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体、其组合物及其用途
|
|
EP3580235B1
(en)
|
2017-02-10 |
2024-05-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
PL3589754T3
(pl)
|
2017-03-01 |
2023-10-09 |
F. Hoffmann-La Roche Ag |
Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
|
|
AR111249A1
(es)
|
2017-03-22 |
2019-06-19 |
Genentech Inc |
Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
|
|
EP3601337A1
(en)
|
2017-03-28 |
2020-02-05 |
Genentech, Inc. |
Methods of treating neurodegenerative diseases
|
|
WO2018178076A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
WO2018178055A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
|
AU2018247767B2
(en)
|
2017-04-03 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to STEAP-1
|
|
MA49039A
(fr)
|
2017-04-04 |
2020-02-12 |
Hoffmann La Roche |
Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap
|
|
HUE060019T2
(hu)
|
2017-04-05 |
2023-01-28 |
Hoffmann La Roche |
Anti-LAG3 antitestek
|
|
PL3606955T3
(pl)
|
2017-04-05 |
2025-02-24 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
|
|
EP3610042A1
(en)
|
2017-04-14 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
|
EP3624820A1
(en)
|
2017-04-21 |
2020-03-25 |
H. Hoffnabb-La Roche Ag |
Use of klk5 antagonists for treatment of a disease
|
|
MX420947B
(es)
|
2017-04-26 |
2025-02-10 |
Eureka Therapeutics Inc |
Constructos que reconocen específicamente glipicano 3 y usos de estos.
|
|
SG10201913677SA
(en)
|
2017-04-27 |
2020-03-30 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
EA201992626A1
(ru)
|
2017-05-05 |
2020-04-24 |
Аллакос Инк. |
Способы и композиции для лечения аллергических заболеваний глаз
|
|
WO2018213304A1
(en)
|
2017-05-16 |
2018-11-22 |
Five Prime Therapeutics, Inc. |
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
|
|
JP7279011B2
(ja)
|
2017-07-10 |
2023-05-22 |
インターナショナル－ドラッグ－ディベロップメント－バイオテック |
抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
|
|
CN111492245A
(zh)
|
2017-07-21 |
2020-08-04 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
CN111448210B
(zh)
|
2017-07-26 |
2024-05-14 |
四十七公司 |
抗SIRP-α抗体及相关方法
|
|
BR112020003533A2
(pt)
|
2017-08-25 |
2020-11-17 |
Five Prime Therapeutics, Inc. |
anticorpos b7-h4 e métodos de uso dos mesmos
|
|
US20200216542A1
(en)
|
2017-09-20 |
2020-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
|
|
CN111954679A
(zh)
|
2017-10-03 |
2020-11-17 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
|
EP3694552A1
(en)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
|
AU2018347521A1
(en)
|
2017-10-12 |
2020-05-07 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
|
CN111315781A
(zh)
|
2017-11-01 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
用靶向性ox40激动剂的组合疗法
|
|
MY205342A
(en)
|
2017-11-01 |
2024-10-16 |
Hoffmann La Roche |
Bispecific 2+1 contorsbodies
|
|
KR20200074997A
(ko)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
|
CN111246884A
(zh)
|
2017-11-01 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
新颖的含有tnf家族配体三聚体的抗原结合分子
|
|
WO2019090329A1
(en)
|
2017-11-06 |
2019-05-09 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
|
WO2019090263A1
(en)
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
EP3710589A4
(en)
|
2017-11-14 |
2021-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-C1S ANTIBODIES AND METHOD OF USING
|
|
BR112020010753A2
(pt)
|
2017-12-01 |
2020-11-24 |
The Regents Of The University Of California |
anticorpos anti-cxcr5 e composições e usos dos mesmos
|
|
CA3081144A1
(en)
|
2017-12-08 |
2019-06-13 |
Argenx Bvba |
Use of fcrn antagonists for treatment of generalized myasthenia gravis
|
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
EP3728317A2
(en)
|
2017-12-21 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Antibodies binding to hla-a2/wt1
|
|
JP7391868B2
(ja)
|
2017-12-22 |
2023-12-05 |
ジョウンセ セラピューティクス， インク． |
Ｌｉｌｒｂ２に対する抗体
|
|
TW201929907A
(zh)
|
2017-12-22 |
2019-08-01 |
美商建南德克公司 |
Pilra結合劑用於治療疾病之用途
|
|
CN111542543B
(zh)
|
2017-12-28 |
2023-12-22 |
南京传奇生物科技有限公司 |
针对pd-l1的抗体及其变体
|
|
AU2018396970B2
(en)
|
2017-12-28 |
2025-09-25 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
|
WO2019129677A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Anti-vegf antibodies and methods of use
|
|
EP3724223A1
(en)
|
2018-01-02 |
2020-10-21 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
EP4495597A3
(en)
|
2018-01-04 |
2025-04-30 |
Iconic Therapeutics LLC |
Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
|
|
SG11202006348VA
(en)
|
2018-01-05 |
2020-07-29 |
Ac Immune Sa |
Misfolded tdp-43 binding molecules
|
|
EP3508499A1
(en)
|
2018-01-08 |
2019-07-10 |
iOmx Therapeutics AG |
Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
CN111699200B
(zh)
|
2018-01-15 |
2023-05-26 |
南京传奇生物科技有限公司 |
针对pd-1的单域抗体和其变体
|
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
|
EP3743088B1
(en)
|
2018-01-26 |
2022-10-12 |
F. Hoffmann-La Roche AG |
Il-22 fc compositions and methods of use
|
|
JP7349995B2
(ja)
|
2018-01-26 |
2023-09-25 |
ジェネンテック， インコーポレイテッド |
ＩＬ－２２ Ｆｃ融合タンパク質及び使用方法
|
|
JP7438953B2
(ja)
|
2018-02-01 |
2024-02-27 |
イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド |
完全ヒト化抗ｂ細胞成熟抗原（ｂｃｍａ）の単鎖抗体およびその応用
|
|
CN118772287A
(zh)
|
2018-02-08 |
2024-10-15 |
豪夫迈·罗氏有限公司 |
双特异性抗原结合分子和使用方法
|
|
EP3749362A1
(en)
|
2018-02-09 |
2020-12-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
CN111757894B
(zh)
|
2018-02-14 |
2025-02-25 |
Abba疗法股份公司 |
抗人类pd-l2抗体
|
|
KR20200123118A
(ko)
|
2018-02-21 |
2020-10-28 |
제넨테크, 인크. |
IL-22 Fc 융합 단백질로 치료를 위한 투약
|
|
WO2019165122A1
(en)
|
2018-02-21 |
2019-08-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
CN111741978A
(zh)
|
2018-02-21 |
2020-10-02 |
戊瑞治疗有限公司 |
B7-h4抗体制剂
|
|
MX2020008730A
(es)
|
2018-02-21 |
2020-12-07 |
Five Prime Therapeutics Inc |
Regímenes de dosificación de anticuerpo b7-h4.
|
|
MX2020008882A
(es)
|
2018-02-26 |
2021-01-08 |
Genentech Inc |
Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
|
EP3759142A1
(en)
|
2018-03-02 |
2021-01-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
|
IL276896B2
(en)
|
2018-03-05 |
2024-06-01 |
Janssen Biotech Inc |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
IL277174B2
(en)
|
2018-03-13 |
2025-12-01 |
Hoffmann La Roche |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
TW202003562A
(zh)
|
2018-03-14 |
2020-01-16 |
中國大陸商北京軒義醫藥科技有限公司 |
抗密連蛋白18.2(cldn18.2)抗體
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
IL277375B2
(en)
|
2018-03-15 |
2025-08-01 |
Chugai Pharmaceutical Co Ltd |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
|
PE20210290A1
(es)
|
2018-03-21 |
2021-02-11 |
Five Prime Therapeutics Inc |
ANTICUERPOS DE UNION A VISTA A pH ACIDO
|
|
JP2021519073A
(ja)
|
2018-03-29 |
2021-08-10 |
ジェネンテック， インコーポレイテッド |
哺乳動物細胞におけるラクトジェニック活性の制御
|
|
AU2019241350B2
(en)
|
2018-03-30 |
2025-10-02 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
|
TWI840351B
(zh)
|
2018-04-05 |
2024-05-01 |
美商奇諾治療有限公司 |
T細胞受體及表現其之工程化細胞
|
|
WO2019197600A1
(en)
|
2018-04-13 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
|
JP2021523138A
(ja)
|
2018-05-11 |
2021-09-02 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｉｌ−２３抗体を使用してうつを治療する方法
|
|
EP3794023A1
(en)
|
2018-05-14 |
2021-03-24 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
DK3794024T5
(da)
|
2018-05-14 |
2024-08-19 |
Werewolf Therapeutics Inc |
Aktiverbare interleukin-2 polypeptider og fremgangsmåder til anvendelse heraf
|
|
JP2021524449A
(ja)
|
2018-05-23 |
2021-09-13 |
アーデーセー セラピューティクス ソシエテ アノニム |
分子アジュバント
|
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
EP3818085A4
(en)
|
2018-06-01 |
2022-03-09 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS
|
|
JP7403479B2
(ja)
|
2018-06-03 |
2023-12-22 |
ランカプ バイオ ベータ リミテッド |
Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体
|
|
JP7372237B2
(ja)
|
2018-06-04 |
2023-10-31 |
中外製薬株式会社 |
細胞質内での半減期が変化した抗原結合分子
|
|
TW202519270A
(zh)
|
2018-06-07 |
2025-05-16 |
美商思進公司 |
喜樹鹼結合物
|
|
MY209122A
(en)
|
2018-06-08 |
2025-06-23 |
argenx BV |
Compositions and methods for treating immune thrombocytopenia
|
|
EP3806904A4
(en)
|
2018-06-18 |
2022-04-27 |
Eureka Therapeutics, Inc. |
PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED CONSTRUCTS AND USES THEREOF
|
|
AU2019288728A1
(en)
|
2018-06-23 |
2021-01-14 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
CN112424228B
(zh)
|
2018-07-04 |
2024-08-09 |
豪夫迈·罗氏有限公司 |
新型双特异性激动性4-1bb抗原结合分子
|
|
CA3104530A1
(en)
|
2018-07-09 |
2020-01-16 |
Five Prime Therapeutics, Inc. |
Antibodies binding to ilt4
|
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
|
AU2019301120A1
(en)
|
2018-07-11 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
|
WO2020016838A2
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained response predictors after treatment with anti-il23 specific antibody
|
|
BR112021000673A2
(pt)
|
2018-07-18 |
2021-04-20 |
Genentech, Inc. |
métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
|
|
WO2020018879A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
|
CN113286824A
(zh)
|
2018-08-03 |
2021-08-20 |
中外制药株式会社 |
包含两个彼此连接的抗原结合结构域的抗原结合分子
|
|
MA50586A
(fr)
|
2018-08-09 |
2020-09-16 |
Regeneron Pharma |
Procédés d'évaluation de l'affinité de liaison d'une variante d'anticorps au récepteur fc néonatal
|
|
KR102697702B1
(ko)
|
2018-08-10 |
2024-08-22 |
추가이 세이야쿠 가부시키가이샤 |
항cd137 항원 결합 분자 및 그의 사용
|
|
WO2020037258A1
(en)
|
2018-08-17 |
2020-02-20 |
Ab Studio Inc. |
Catabodies and methods of use thereof
|
|
TW202023625A
(zh)
|
2018-08-23 |
2020-07-01 |
美商西雅圖遺傳學公司 |
抗tigit抗體
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
CN112673022B
(zh)
|
2018-09-10 |
2024-07-09 |
南京传奇生物科技有限公司 |
针对cd33的单结构域抗体及其构建体
|
|
CN112955747A
(zh)
|
2018-09-19 |
2021-06-11 |
豪夫迈·罗氏有限公司 |
膀胱癌的治疗和诊断方法
|
|
MX2021003213A
(es)
|
2018-09-21 |
2021-05-12 |
Genentech Inc |
Metodos de diagnostico para cancer de mama triple negativo.
|
|
JP2022502488A
(ja)
|
2018-09-21 |
2022-01-11 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
粘液を透過するのを制限するための合成結合剤
|
|
MD3883606T3
(ro)
|
2018-09-24 |
2024-03-31 |
Janssen Biotech Inc |
Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
PE20211863A1
(es)
|
2018-10-01 |
2021-09-21 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
|
|
CN112654641A
(zh)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
具有与cd40的三价结合的双特异性抗原结合分子
|
|
EP3632929A1
(en)
|
2018-10-02 |
2020-04-08 |
Ospedale San Raffaele S.r.l. |
Antibodies and uses thereof
|
|
CN112804989A
(zh)
|
2018-10-05 |
2021-05-14 |
戊瑞治疗有限公司 |
抗fgfr2抗体制剂
|
|
US11130802B2
(en)
|
2018-10-10 |
2021-09-28 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants
|
|
SG11202103153VA
(en)
|
2018-10-15 |
2021-04-29 |
Five Prime Therapeutics Inc |
Combination therapy for cancer
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
KR102467349B1
(ko)
|
2018-10-29 |
2022-11-16 |
에프. 호프만-라 로슈 아게 |
항체 제형
|
|
US20210395390A1
(en)
|
2018-10-31 |
2021-12-23 |
Bayer Aktiengesellschaft |
Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
|
|
EP4640698A3
(en)
|
2018-11-16 |
2026-02-25 |
Memorial Sloan Kettering Cancer Center |
Antibodies to mucin-16 and methods of use thereof
|
|
BR112021009287A2
(pt)
|
2018-11-20 |
2021-10-26 |
Janssen Biotech, Inc. |
Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
|
|
CA3183309A1
(en)
|
2018-11-27 |
2020-06-04 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
|
|
EP3891185A2
(en)
|
2018-12-05 |
2021-10-13 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for cancer immunotherapy
|
|
US12234289B2
(en)
|
2018-12-07 |
2025-02-25 |
Ono Pharmaceutical Co., Ltd. |
Immunosuppresive agent
|
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
EP3897722A4
(en)
|
2018-12-18 |
2022-09-14 |
Janssen Biotech, Inc. |
SAFE AND EFFECTIVE METHOD OF TREATMENT OF LUPUS WITH ANTI-IL12/IL23 ANTIBODIES
|
|
EP3898667A2
(en)
|
2018-12-20 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Modified antibody fcs and methods of use
|
|
EP3883609A2
(en)
|
2018-12-20 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
|
TWI829831B
(zh)
|
2018-12-21 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合cd3之抗體
|
|
AR117468A1
(es)
|
2018-12-21 |
2021-08-11 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A VEGF Y A IL-1b Y MÉTODOS DE UTILIZACIÓN
|
|
JP2022513495A
(ja)
|
2018-12-21 |
2022-02-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
腫瘍標的化スーパーアゴニストｃｄ２８抗原結合分子
|
|
WO2020127618A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Tumor-targeted agonistic cd28 antigen binding molecules
|
|
KR20210141447A
(ko)
|
2018-12-26 |
2021-11-23 |
실리오 디벨럽먼트, 인크. |
항-ctla4 항체 및 이의 사용 방법
|
|
WO2020141145A1
(en)
|
2018-12-30 |
2020-07-09 |
F. Hoffmann-La Roche Ag |
Anti-rabbit cd19 antibodies and methods of use
|
|
MX2021008434A
(es)
|
2019-01-14 |
2021-09-23 |
Genentech Inc |
Metodos para tratar el cancer con un antagonista de union al eje de pd-1 y una vacuna de arn.
|
|
CA3126778A1
(en)
|
2019-01-17 |
2020-07-23 |
Bayer Aktiengesellschaft |
Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
|
|
CN113795511B
(zh)
|
2019-01-23 |
2024-07-23 |
大有华夏生物医药集团有限公司 |
抗pd-l1双抗体及其用途
|
|
EP3915581A4
(en)
|
2019-01-24 |
2023-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
NOVEL CANCER ANTIGENS AND ANTIBODIES OF THESE ANTIGENS
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
CN113365660A
(zh)
|
2019-01-29 |
2021-09-07 |
朱诺治疗学股份有限公司 |
对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
EP3927744A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
BR112021016923A2
(pt)
|
2019-02-27 |
2021-11-03 |
Genentech Inc |
Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
|
|
EP3935385A1
(en)
|
2019-03-08 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
|
|
MX2021010996A
(es)
|
2019-03-14 |
2021-11-04 |
Genentech Inc |
Tratamiento de cancer con anticuerpos biespecificos contra her2xcd3 en combinacion con mab anti-her2.
|
|
CA3133395A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-il12/il23 antibody compositions
|
|
MA55383A
(fr)
|
2019-03-18 |
2022-01-26 |
Janssen Biotech Inc |
Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
|
|
GB2589049C
(en)
|
2019-04-11 |
2024-02-21 |
argenx BV |
Anti-IgE antibodies
|
|
EP3952996A1
(en)
|
2019-04-12 |
2022-02-16 |
F. Hoffmann-La Roche AG |
Bispecific antigen binding molecules comprising lipocalin muteins
|
|
MX2021012692A
(es)
|
2019-04-19 |
2021-11-12 |
Genentech Inc |
Anticuerpos anti-mertk y sus metodos de uso.
|
|
CA3137397A1
(en)
|
2019-04-19 |
2020-10-22 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor that recognizes engineered site in antibody
|
|
WO2020227228A2
(en)
|
2019-05-03 |
2020-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
TWI879768B
(zh)
|
2019-05-03 |
2025-04-11 |
美商建南德克公司 |
用抗pd-l1抗體治療癌症之方法
|
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
|
MX2021013766A
(es)
|
2019-05-14 |
2022-02-21 |
Werewolf Therapeutics Inc |
Restos de separacion y metodos de uso de los mismos.
|
|
BR112021021689A2
(pt)
|
2019-05-15 |
2022-03-22 |
Chugai Pharmaceutical Co Ltd |
Molécula de ligação a antígeno, composição farmacêutica, e método
|
|
US12559544B2
(en)
|
2019-05-21 |
2026-02-24 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
|
US20220315648A1
(en)
|
2019-05-23 |
2022-10-06 |
Ac Immune Sa |
Anti-TDP-43 Binding Molecules and Uses Thereof
|
|
US11780911B2
(en)
|
2019-05-23 |
2023-10-10 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
|
AU2020288749A1
(en)
|
2019-06-04 |
2022-02-03 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
|
|
CN114126647A
(zh)
|
2019-06-07 |
2022-03-01 |
阿尔金克斯有限公司 |
适用于皮下施用的FcRn抑制剂的药物制剂
|
|
WO2020260329A1
(en)
|
2019-06-26 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Fusion of an antibody binding cea and 4-1bbl
|
|
EP3990492A1
(en)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
|
AU2020299382A1
(en)
|
2019-07-02 |
2022-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind EGFRvIII and their use
|
|
EP3994171A1
(en)
|
2019-07-05 |
2022-05-11 |
iOmx Therapeutics AG |
Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
|
|
WO2021004446A1
(en)
|
2019-07-09 |
2021-01-14 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing pseudomonas pcrv and uses thereof
|
|
JPWO2021010326A1
(enExample)
|
2019-07-12 |
2021-01-21 |
|
|
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
US12410241B2
(en)
|
2019-07-26 |
2025-09-09 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus D68
|
|
SG11202112491WA
(en)
|
2019-07-31 |
2021-12-30 |
Hoffmann La Roche |
Antibodies binding to gprc5d
|
|
WO2021018925A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
JP7181438B2
(ja)
|
2019-08-06 |
2022-11-30 |
アプリノイア セラピューティクス リミテッド |
病理学的タウ種に結合する抗体及びその使用
|
|
CA3146616A1
(en)
|
2019-09-12 |
2021-03-18 |
Matthew Dominic CASCINO |
Compositions and methods of treating lupus nephritis
|
|
CN114423791B
(zh)
|
2019-09-18 |
2026-01-09 |
豪夫迈·罗氏有限公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法
|
|
CA3149719A1
(en)
|
2019-09-19 |
2021-03-25 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
MX2022003266A
(es)
|
2019-09-20 |
2022-04-11 |
Genentech Inc |
Dosis para anticuerpos anti-triptasa.
|
|
TW202126690A
(zh)
|
2019-09-27 |
2021-07-16 |
美商建南德克公司 |
用抗ｔｉｇｉｔ和抗ｐｄ－ｌ１拮抗劑抗體給藥治療
|
|
WO2021076196A1
(en)
|
2019-10-18 |
2021-04-22 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
CN115066613A
(zh)
|
2019-11-06 |
2022-09-16 |
基因泰克公司 |
用于治疗血液癌症的诊断和治疗方法
|
|
TWI895295B
(zh)
|
2019-11-12 |
2025-09-01 |
美商方得生醫療公司 |
偵測編碼新生抗原之融合基因之方法
|
|
AU2020384375A1
(en)
|
2019-11-14 |
2022-05-26 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
CA3154526A1
(en)
|
2019-11-15 |
2021-05-20 |
Enthera S.R.L. |
Tmem219 antibodies and therapeutic uses thereof
|
|
EP3822288A1
(en)
|
2019-11-18 |
2021-05-19 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
|
|
EP4061839A1
(en)
|
2019-11-21 |
2022-09-28 |
Enthera S.R.L. |
Igfbp3 antibodies and therapeutic uses thereof
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
IL293430A
(en)
|
2019-12-06 |
2022-07-01 |
Juno Therapeutics Inc |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
|
CN115335399A
(zh)
|
2019-12-06 |
2022-11-11 |
朱诺治疗学股份有限公司 |
针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
|
|
PE20221511A1
(es)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y metodos de uso
|
|
KR20220100963A
(ko)
|
2019-12-18 |
2022-07-18 |
에프. 호프만-라 로슈 아게 |
Hla-a2/mage-a4에 결합하는 항체
|
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
|
EP4082570B1
(en)
|
2019-12-27 |
2026-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody and use thereof
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
ES2992247T3
(es)
|
2020-01-08 |
2024-12-11 |
argenx BV |
Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
|
|
EP4087866A1
(en)
|
2020-01-09 |
2022-11-16 |
F. Hoffmann-La Roche AG |
New 4-1bbl trimer-containing antigen binding molecules
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
EP4096708A1
(en)
|
2020-01-31 |
2022-12-07 |
Genentech, Inc. |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
|
EP4097143A1
(en)
|
2020-01-31 |
2022-12-07 |
The Cleveland Clinic Foundation |
Anti-müllerian hormone receptor 2 antibodies and methods of use
|
|
AU2021220847A1
(en)
|
2020-02-11 |
2022-09-01 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2)
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
IL295023A
(en)
|
2020-02-14 |
2022-09-01 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and their uses
|
|
WO2021168292A1
(en)
|
2020-02-20 |
2021-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Epstein-barr virus monoclonal antibodies and uses thereof
|
|
EP3868396A1
(en)
|
2020-02-20 |
2021-08-25 |
Enthera S.R.L. |
Inhibitors and uses thereof
|
|
CN115151573A
(zh)
|
2020-02-28 |
2022-10-04 |
上海复宏汉霖生物技术股份有限公司 |
抗cd137构建体、多特异性抗体及其用途
|
|
BR112022016491A2
(pt)
|
2020-02-28 |
2022-10-11 |
Shanghai Henlius Biotech Inc |
Construto anti-cd137 e usos do mesmo
|
|
WO2021178896A1
(en)
|
2020-03-06 |
2021-09-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
|
CA3174680A1
(en)
|
2020-03-13 |
2021-09-16 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
PE20230259A1
(es)
|
2020-03-19 |
2023-02-07 |
Genentech Inc |
Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso
|
|
US20230174656A1
(en)
|
2020-03-23 |
2023-06-08 |
Genentech, Inc. |
Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
|
|
US20230125415A1
(en)
|
2020-03-23 |
2023-04-27 |
Genentech, Inc. |
Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
|
|
JP2023518815A
(ja)
|
2020-03-23 |
2023-05-08 |
ジェネンテック， インコーポレイテッド |
Ｉｌ６アンタゴニストによるｃｏｖｉｄ－１９肺炎を含む肺炎の治療方法
|
|
US11999787B2
(en)
|
2020-03-24 |
2024-06-04 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
|
JP2023518841A
(ja)
|
2020-03-26 |
2023-05-08 |
ジェネンテック， インコーポレイテッド |
宿主細胞タンパク質が減少した修飾哺乳動物細胞
|
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
|
DK4045533T5
(da)
|
2020-03-26 |
2024-07-29 |
Univ Vanderbilt |
Humane monoklonale antistoffer mod svær akut respiratorisk syndrom-coronavirus 2 (sars-cov-2)
|
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
|
EP4139359A1
(en)
|
2020-04-24 |
2023-03-01 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
US12559575B2
(en)
|
2020-04-27 |
2026-02-24 |
The Regents Of The University Of California |
Isoform-independent antibodies to lipoprotein(a)
|
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック， インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
|
JP2023527962A
(ja)
|
2020-05-03 |
2023-07-03 |
レヴィーナ （スジョウ） バイオファーマ カンパニー， リミテッド |
抗ｔｒｏｐ２抗体を含む抗体薬物複合体（ａｄｃ）、かかるａｄｃを含む組成物、ならびにそれらを作製および使用する方法
|
|
CA3181949A1
(en)
|
2020-05-05 |
2021-11-11 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
EP4153312A1
(en)
|
2020-05-17 |
2023-03-29 |
AstraZeneca UK Limited |
Sars-cov-2 antibodies and methods of selecting and using the same
|
|
CN115768466A
(zh)
|
2020-05-21 |
2023-03-07 |
詹森生物科技公司 |
用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
|
|
EP4157881A4
(en)
|
2020-05-27 |
2024-10-09 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
ANTIBODIES THAT SPECIFICALLY RECOGNIZE NERVE GROWTH FACTOR AND THEIR USES
|
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
|
BR112022024629A2
(pt)
|
2020-06-02 |
2023-02-23 |
Dynamicure Biotechnology Llc |
Construtos anti-cd93 e seus usos
|
|
EP4161644A2
(en)
|
2020-06-08 |
2023-04-12 |
F. Hoffmann-La Roche AG |
Anti-hbv antibodies and methods of use
|
|
EP4165415A1
(en)
|
2020-06-12 |
2023-04-19 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
TWI852680B
(zh)
|
2020-06-19 |
2024-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與 cd3 及 cd19 結合之抗體
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
KR20230025665A
(ko)
|
2020-06-19 |
2023-02-22 |
에프. 호프만-라 로슈 아게 |
Cd3에 결합하는 항체
|
|
AU2021291005A1
(en)
|
2020-06-19 |
2023-01-05 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3 and FolR1
|
|
IL297880A
(en)
|
2020-06-23 |
2023-01-01 |
Hoffmann La Roche |
Agonistic cd28 antigen binding molecules targeting her2
|
|
US20220041672A1
(en)
|
2020-06-24 |
2022-02-10 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
|
CN115916830A
(zh)
|
2020-06-25 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
抗cd3/抗cd28双特异性抗原结合分子
|
|
EP4175668A1
(en)
|
2020-07-06 |
2023-05-10 |
iOmx Therapeutics AG |
Antibodies binding igv of igsf11 (vsig3) and uses thereof
|
|
EP4178985A1
(en)
|
2020-07-10 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
|
US20220025035A1
(en)
|
2020-07-13 |
2022-01-27 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
|
|
MX2023000617A
(es)
|
2020-07-17 |
2023-02-13 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso.
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
EP4188550A1
(en)
|
2020-07-29 |
2023-06-07 |
Dynamicure Biotechnology LLC |
Anti-cd93 constructs and uses thereof
|
|
US20220073603A1
(en)
|
2020-07-30 |
2022-03-10 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
|
|
JP2023536602A
(ja)
|
2020-08-03 |
2023-08-28 |
ジェネンテック， インコーポレイテッド |
リンパ腫のための診断及び治療方法
|
|
US20230324408A1
(en)
|
2020-08-05 |
2023-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
|
IL300260A
(en)
|
2020-08-07 |
2023-03-01 |
Genentech Inc |
FLT3 ligand fusion proteins and methods of use
|
|
US20220041694A1
(en)
|
2020-08-10 |
2022-02-10 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies for treatment and prevention of covid-19
|
|
EP4196162A1
(en)
|
2020-08-14 |
2023-06-21 |
AC Immune SA |
Humanized anti-tdp-43 binding molecules and uses thereof
|
|
EP4204448A2
(en)
|
2020-08-27 |
2023-07-05 |
cureab GmbH |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
|
CN116648507A
(zh)
|
2020-08-28 |
2023-08-25 |
基因泰克公司 |
宿主细胞蛋白的CRISPR/Cas9多重敲除
|
|
CN116323663A
(zh)
|
2020-09-04 |
2023-06-23 |
豪夫迈·罗氏有限公司 |
与vegf-a和ang2结合的抗体及其使用方法
|
|
US20240010750A1
(en)
|
2020-09-15 |
2024-01-11 |
Bayer Aktiengesellschaft |
Novel anti-a2ap antibodies and uses thereof
|
|
CN116685351A
(zh)
|
2020-09-17 |
2023-09-01 |
基因泰克公司 |
Empacta的结果：一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究
|
|
CA3193569A1
(en)
|
2020-09-28 |
2022-03-31 |
Xiaofeng Liu |
Anti-sclerostin constructs and uses thereof
|
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
WO2022084210A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
|
|
US20250270302A1
(en)
|
2020-10-20 |
2025-08-28 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
|
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
EP4240762A1
(en)
|
2020-11-03 |
2023-09-13 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
|
|
CA3196539A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
IL302400A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
|
|
CA3196191A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
WO2022101458A1
(en)
|
2020-11-16 |
2022-05-19 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted cd40 agonists
|
|
TW202235431A
(zh)
|
2020-11-25 |
2022-09-16 |
美商艾希利歐發展股份有限公司 |
腫瘤特異性可裂解連接子
|
|
JP2023553861A
(ja)
|
2020-12-02 |
2023-12-26 |
上海復宏漢霖生物技術股▲フン▼有限公司 |
抗ＧＡＲＰ／ＴＧＦβ抗体及び使用方法
|
|
MX2023006294A
(es)
|
2020-12-02 |
2023-06-13 |
Glaxosmithkline Ip Dev Ltd |
Proteinas de union a il-7 y su uso en tratamientos medicos.
|
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
TW202237639A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
|
MX2023007846A
(es)
|
2021-01-06 |
2023-07-07 |
Hoffmann La Roche |
Tratamiento conjunto que usa un anticuerpo biespecifico contra pd1-lag3 y un anticuerpo biespecifico de linfocitos t cd20.
|
|
EP4277705A1
(en)
|
2021-01-12 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Split antibodies which bind to cancer cells and target radionuclides to said cells
|
|
WO2022152701A1
(en)
|
2021-01-13 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Combination therapy
|
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
|
CA3206395A1
(en)
|
2021-01-28 |
2022-08-04 |
Hassan JUMAA-WEINACHT |
Method and means for modulating b-cell mediated immune responses
|
|
CN117120084A
(zh)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
用于调节b细胞介导的免疫应答的方法和手段
|
|
EP4288458A1
(en)
|
2021-02-03 |
2023-12-13 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
CN117642178A
(zh)
|
2021-02-09 |
2024-03-01 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向冠状病毒刺突蛋白的抗体
|
|
CN117396502A
(zh)
|
2021-02-09 |
2024-01-12 |
佐治亚大学研究基金会有限公司 |
针对肺炎球菌抗原的人类单克隆抗体
|
|
MX2023009497A
(es)
|
2021-02-15 |
2023-08-23 |
Takeda Pharmaceuticals Co |
Composiciones y metodos de terapia celular para modular la se?alizacion del factor de crecimiento transformador-beta (tgf-beta).
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US20240317847A1
(en)
|
2021-02-26 |
2024-09-26 |
Bayer Aktiengesellschaft |
INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDING
|
|
TW202246324A
(zh)
|
2021-03-01 |
2022-12-01 |
美商艾希利歐發展股份有限公司 |
用於治療癌症的經掩蔽之ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
|
|
EP4301467A1
(en)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
|
CN117440832A
(zh)
|
2021-03-03 |
2024-01-23 |
索伦托药业有限公司 |
包括抗bcma抗体的抗体-药物缀合物
|
|
WO2022187863A1
(en)
|
2021-03-05 |
2022-09-09 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
|
WO2022187591A1
(en)
|
2021-03-05 |
2022-09-09 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
|
WO2022190033A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック， インコーポレイテッド |
抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
|
|
WO2022190034A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
|
IL305283A
(en)
|
2021-03-15 |
2023-10-01 |
Genentech Inc |
Compositions and methods for the treatment of lupus nephritis
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
TW202300648A
(zh)
|
2021-03-25 |
2023-01-01 |
美商當康生物科技有限公司 |
抗-igfbp7構築體及其用途
|
|
CA3215274A1
(en)
|
2021-03-30 |
2022-10-06 |
Bayer Aktiengesellschaft |
Anti-sema3a antibodies and uses thereof
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
WO2022225880A1
(en)
|
2021-04-19 |
2022-10-27 |
Genentech, Inc. |
Modified mammalian cells
|
|
JP2024514281A
(ja)
|
2021-04-23 |
2024-04-01 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｎｋ細胞係合剤関連の有害作用の防止または軽減
|
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
CA3218170A1
(en)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
WO2022241235A1
(en)
|
2021-05-14 |
2022-11-17 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
JP2024518545A
(ja)
|
2021-05-14 |
2024-05-01 |
ジェネンテック， インコーポレイテッド |
Ｔｒｅｍ２のアゴニスト
|
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
|
KR20240010469A
(ko)
|
2021-05-21 |
2024-01-23 |
제넨테크, 인크. |
관심 재조합 생성물의 생성을 위한 변형된 세포
|
|
JP2024521187A
(ja)
|
2021-05-28 |
2024-05-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
ガンの治療のための組み合わせ療法
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
|
CA3216220A1
(en)
|
2021-06-09 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
|
MX2023014658A
(es)
|
2021-06-11 |
2024-01-12 |
Genentech Inc |
Metodo para tratar la enfermedad pulmonar obstructiva cronica con un antagonista de st2.
|
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
US12227574B2
(en)
|
2021-06-17 |
2025-02-18 |
Amberstone Biosciences, Inc. |
Anti-CD3 constructs and uses thereof
|
|
CN117545779B
(zh)
|
2021-06-25 |
2025-04-04 |
中外制药株式会社 |
抗ctla-4抗体的用途
|
|
CN117616123B
(zh)
|
2021-06-25 |
2024-11-08 |
中外制药株式会社 |
抗ctla-4抗体
|
|
US20250011448A1
(en)
|
2021-07-08 |
2025-01-09 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing tnfr2 and uses thereof
|
|
CN117916260A
(zh)
|
2021-07-09 |
2024-04-19 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
|
JP2024530402A
(ja)
|
2021-07-12 |
2024-08-21 |
ジェネンテック， インコーポレイテッド |
抗体－リパーゼ結合を減少させるための構造
|
|
CA3224853A1
(en)
|
2021-07-14 |
2023-01-19 |
Gautham GAMPA |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
|
WO2023284714A1
(zh)
|
2021-07-14 |
2023-01-19 |
舒泰神（北京）生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
|
AU2022315528A1
(en)
|
2021-07-22 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
|
KR20240107093A
(ko)
|
2021-08-05 |
2024-07-08 |
고 테라퓨틱스, 인크. |
항-글리코-muc4 항체 및 그의 용도
|
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
EP4384553A1
(en)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
|
WO2023017484A1
(en)
|
2021-08-13 |
2023-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras
|
|
EP4384223B1
(en)
|
2021-08-13 |
2025-10-01 |
GlaxoSmithKline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
|
CN117858905A
(zh)
|
2021-08-19 |
2024-04-09 |
豪夫迈·罗氏有限公司 |
多价抗变体fc区抗体及使用方法
|
|
CA3229448A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
MX2024002295A
(es)
|
2021-08-27 |
2024-03-07 |
Genentech Inc |
Metodos para tratar las patologias de tau.
|
|
JP2024534853A
(ja)
|
2021-08-30 |
2024-09-26 |
ジェネンテック， インコーポレイテッド |
抗ポリビキチン多重特異性抗体
|
|
JP2024534910A
(ja)
|
2021-09-03 |
2024-09-26 |
ジーオー セラピューティクス，インコーポレイテッド |
抗グリコｌａｍｐ１抗体およびその使用
|
|
KR20240109604A
(ko)
|
2021-09-03 |
2024-07-11 |
고 테라퓨틱스, 인크. |
항-글리코-cMET 항체 및 그의 용도
|
|
AU2022345251A1
(en)
|
2021-09-17 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
|
|
WO2023056361A1
(en)
|
2021-09-29 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Anti-hsp70 antibodies and therapeutic uses thereof
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
EP4412713A1
(en)
|
2021-10-05 |
2024-08-14 |
GlaxoSmithKline Intellectual Property Development Ltd |
Combination therapies for treating cancer
|
|
WO2023058723A1
(ja)
|
2021-10-08 |
2023-04-13 |
中外製薬株式会社 |
プレフィルドシリンジ製剤の調製方法
|
|
KR20240099352A
(ko)
|
2021-10-29 |
2024-06-28 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 크론병을 치료하는 방법
|
|
WO2022078524A2
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
WO2023078279A1
(zh)
*
|
2021-11-04 |
2023-05-11 |
澄交生物科技股份有限公司 |
免疫原性组合物及其用途
|
|
CA3236417A1
(en)
|
2021-11-05 |
2023-05-11 |
American Diagnostics & Therapy, Llc (Adxrx) |
Monoclonal antibodies against carcinoembryonic antigens, and their uses
|
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防ｃｏｖｉｄ—１９之組成物
|
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
WO2023084488A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
IL312692A
(en)
|
2021-11-16 |
2024-07-01 |
Genentech Inc |
Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab
|
|
KR20240100369A
(ko)
|
2021-11-16 |
2024-07-01 |
에이씨 이뮨 에스에이 |
치료 및 진단을 위한 신규한 분자
|
|
KR20240103043A
(ko)
|
2021-11-23 |
2024-07-03 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
|
|
EP4437006A1
(en)
|
2021-11-26 |
2024-10-02 |
F. Hoffmann-La Roche AG |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
|
EP4445911A4
(en)
|
2021-12-06 |
2025-10-22 |
Beijing Solobio Genetechnology Co Ltd |
BISPECIFIC ANTIBODY THAT BINDS SPECIFICALLY TO KLEBSIELLA PNEUMONIAE O1 AND O2 ANTIGENS AND COMPOSITION
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
EP4448579A4
(en)
|
2021-12-17 |
2026-02-18 |
Shanghai Henlius Biotech Inc |
ANTI-OX40 ANTIBODIES AND METHODS OF USE
|
|
CA3240585A1
(en)
|
2021-12-17 |
2023-06-22 |
Wenfeng Xu |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
|
CR20240246A
(es)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
|
|
UY40097A
(es)
|
2022-01-07 |
2023-07-14 |
Johnson & Johnson Entpr Innovation Inc |
Materiales y métodos de proteínas de unión a il-1b
|
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
|
EP4476251A1
(en)
|
2022-02-10 |
2024-12-18 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
|
TW202342519A
(zh)
|
2022-02-16 |
2023-11-01 |
瑞士商Ａｃ 免疫有限公司 |
人源化抗ｔｄｐ－４３結合分子及其用途
|
|
EP4479431A1
(en)
|
2022-02-18 |
2024-12-25 |
Rakuten Medical, Inc. |
Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
|
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Ｒｑ生物科技有限公司 |
抗體
|
|
CN119136836A
(zh)
|
2022-02-25 |
2024-12-13 |
葛兰素史克知识产权发展有限公司 |
用于c-c趋化因子受体2表达细胞的细胞毒性靶向嵌合体
|
|
WO2023161881A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
|
WO2023161877A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for integrin avb6-expressing cells
|
|
WO2023161878A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for folate receptor-expressing cells
|
|
WO2023161875A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
|
|
WO2023161879A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
|
|
WO2023161876A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for cxcr3-expressing cells
|
|
US20250205350A1
(en)
|
2022-03-10 |
2025-06-26 |
Vivasor, Inc. |
Antibody-Drug Conjugates and Uses Thereof
|
|
MX2024011468A
(es)
|
2022-03-23 |
2024-09-25 |
Hoffmann La Roche |
Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
|
|
EP4499708A1
(en)
|
2022-03-25 |
2025-02-05 |
Shanghai Henlius Biotech, Inc. |
Anti-msln antibodies and methods of use
|
|
EP4499227A1
(en)
|
2022-03-26 |
2025-02-05 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Bispecific antibodies to hiv-1 env and their use
|
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
JP2025511000A
(ja)
|
2022-03-28 |
2025-04-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
インターフェロンガンマバリアントおよびこれを含む抗原結合分子
|
|
CN119698430A
(zh)
|
2022-03-30 |
2025-03-25 |
詹森生物科技公司 |
用il-23特异性抗体治疗轻度至中度银屑病的方法
|
|
KR20240169042A
(ko)
|
2022-04-01 |
2024-12-02 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
|
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
|
AU2023251832A1
(en)
|
2022-04-13 |
2024-10-17 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
|
AR129062A1
(es)
|
2022-04-13 |
2024-07-10 |
Genentech Inc |
Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso
|
|
WO2023203177A1
(en)
|
2022-04-20 |
2023-10-26 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
|
|
CN119836433A
(zh)
|
2022-04-29 |
2025-04-15 |
阿斯利康(英国)有限公司 |
Sars-cov-2抗体及其使用方法
|
|
JP2025514374A
(ja)
|
2022-04-29 |
2025-05-02 |
２３アンドミー・インコーポレイテッド |
抗原結合タンパク質
|
|
CA3257258A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-Ly6E antibodies, immunoconjugates, and their uses
|
|
CN119487065A
(zh)
|
2022-05-09 |
2025-02-18 |
舒泰神（北京）生物制药股份有限公司 |
特异性识别gdf15的抗体及其应用
|
|
AU2022458320A1
(en)
|
2022-05-11 |
2024-11-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AR129268A1
(es)
|
2022-05-11 |
2024-08-07 |
Hoffmann La Roche |
Anticuerpo que se une a vegf-a e il6 y métodos de uso
|
|
US20230374122A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
|
|
AR129445A1
(es)
|
2022-05-27 |
2024-08-28 |
Glaxosmithkline Ip Dev Ltd |
USO DE PROTEÍNAS DE UNIÓN A TNF-a Y PROTEÍNAS DE UNIÓN A IL-7 EN EL TRATAMIENTO MÉDICO
|
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
|
IL317449A
(en)
|
2022-06-07 |
2025-02-01 |
Genentech Inc |
Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
|
|
US20250382354A1
(en)
|
2022-06-08 |
2025-12-18 |
Institute For Research In Biomedicine (Irb) |
Cross-specific antibodies, uses and methods for discovery thereof
|
|
CA3258004A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
FCRN/HSA BONDING MOLECULES AND METHODS OF USE
|
|
EP4554978A1
(en)
|
2022-07-13 |
2025-05-21 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
|
IL318252A
(en)
|
2022-07-19 |
2025-03-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
|
CR20250056A
(es)
|
2022-07-22 |
2025-03-19 |
Genentech Inc |
Moléculas de unión al antígeno anti-steap1 y sus usos.
|
|
CN120865421A
(zh)
|
2022-07-22 |
2025-10-31 |
百时美施贵宝公司 |
结合至人类pad4的抗体及其用途
|
|
EP4565329A1
(en)
|
2022-08-01 |
2025-06-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
|
JP2025525969A
(ja)
|
2022-08-05 |
2025-08-07 |
ヤンセン バイオテツク，インコーポレーテツド |
脳腫瘍を治療するためのｃｄ９８結合構築物
|
|
MA71684A
(fr)
|
2022-08-05 |
2025-05-30 |
Janssen Biotech, Inc. |
Protéines de liaison de récepteur de transferrine pour traitement de tumeurs cérébrales
|
|
IL319125A
(en)
|
2022-08-22 |
2025-04-01 |
Abdera Therapeutics Inc |
DLL3 binding molecules and their uses
|
|
EP4577569A1
(en)
|
2022-08-25 |
2025-07-02 |
GlaxoSmithKline Intellectual Property Development Ltd |
Antigen binding proteins and uses thereof
|
|
AU2023329484A1
(en)
|
2022-08-26 |
2025-02-20 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
|
US20260078185A1
(en)
|
2022-09-07 |
2026-03-19 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
WO2024067344A1
(zh)
|
2022-09-27 |
2024-04-04 |
舒泰神（北京）生物制药股份有限公司 |
特异性识别light的抗体及其应用
|
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
|
KR20250093362A
(ko)
|
2022-10-20 |
2025-06-24 |
베이징 솔로바이오 진테크놀로지 컴퍼니 리미티드 |
TRAIL 또는 FasL에 특이적으로 결합하는 항체 조합 및 이중특이 항체
|
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
KR20250099702A
(ko)
|
2022-11-04 |
2025-07-02 |
길리애드 사이언시즈, 인코포레이티드 |
항-ccr8 항체, 화학요법 및 면역요법 조합을 사용하는 항암 요법
|
|
AU2023375342A1
(en)
|
2022-11-08 |
2025-04-24 |
F. Hoffmann-La Roche Ag |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
|
US20260055182A1
(en)
|
2022-11-09 |
2026-02-26 |
Cis Biopharma Ag |
Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
EP4619045A1
(en)
|
2022-11-17 |
2025-09-24 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
|
IL321059A
(en)
|
2022-11-22 |
2025-07-01 |
Janssen Biotech Inc |
Method for treating ulcerative colitis with a specific anti-IL23 antibody
|
|
CN120265651A
(zh)
|
2022-11-25 |
2025-07-04 |
中外制药株式会社 |
用于生产蛋白质的方法
|
|
CN119546630A
(zh)
|
2022-12-08 |
2025-02-28 |
南京诺唯赞生物科技股份有限公司 |
特异性结合rsv的抗体
|
|
EP4638491A1
(en)
|
2022-12-19 |
2025-10-29 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Monoclonal antibodies for treating sars-cov-2 infection
|
|
JP2025542200A
(ja)
|
2022-12-23 |
2025-12-25 |
イオックス セラピューティクス アーゲー |
白血球免疫グロブリン様受容体サブファミリーＢｌ（ＬＩＬＢ１）及びＬＩＬＢ２を標的とする交差特異的抗原結合タンパク質（ＡＢＰ）、その組合せ及び使用
|
|
EP4491230A1
(en)
|
2023-07-14 |
2025-01-15 |
iOmx Therapeutics AG |
Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
|
|
IL321951A
(en)
|
2023-01-18 |
2025-09-01 |
Genentech Inc |
Multispecific antibodies and their uses
|
|
JP2026505747A
(ja)
|
2023-01-25 |
2026-02-18 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｓｆ１ｒおよびｃｄ３に結合する抗体
|
|
TW202448960A
(zh)
|
2023-02-07 |
2024-12-16 |
美商Ｇｏ治療公司 |
包括抗醣MUC4抗體及MIC蛋白α1-α2結構域之抗體融合蛋白及其用途
|
|
WO2024184494A1
(en)
|
2023-03-08 |
2024-09-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules and uses thereof
|
|
EP4428159A1
(en)
|
2023-03-10 |
2024-09-11 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Melanoma targeting human antibodies and therapeutic uses thereof
|
|
EP4428158A1
(en)
|
2023-03-10 |
2024-09-11 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Lung cancer targeting human antibodies and therapeutic uses thereof
|
|
WO2024191785A1
(en)
|
2023-03-10 |
2024-09-19 |
Genentech, Inc. |
Fusions with proteases and uses thereof
|
|
EP4680635A1
(en)
|
2023-03-13 |
2026-01-21 |
F. Hoffmann-La Roche AG |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
|
WO2024206788A1
(en)
|
2023-03-31 |
2024-10-03 |
Genentech, Inc. |
Anti-alpha v beta 8 integrin antibodies and methods of use
|
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
EP4687997A2
(en)
|
2023-04-05 |
2026-02-11 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211234A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024212827A1
(en)
|
2023-04-12 |
2024-10-17 |
Shanghai Kangabio Co., Limited |
Multifunctional molecules comprising masked interleukin 12 and methods of use
|
|
CN121263210A
(zh)
|
2023-04-17 |
2026-01-02 |
沛科生物公司 |
抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
|
|
EP4698225A1
(en)
|
2023-04-21 |
2026-02-25 |
GlaxoSmithKline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
|
|
WO2024218361A1
(en)
|
2023-04-21 |
2024-10-24 |
Glaxosmithkline Intellectual Property Development Limited |
Bispecific cytotoxicity targeting chimeras
|
|
TW202448949A
(zh)
|
2023-05-05 |
2024-12-16 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
AU2024269754A1
(en)
|
2023-05-08 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Targeted interferon alpha fusion proteins and methods of use
|
|
IL324490A
(en)
|
2023-05-10 |
2026-01-01 |
Genentech Inc |
Methods and preparations for treating cancer
|
|
TW202509065A
(zh)
|
2023-05-16 |
2025-03-01 |
瑞士商赫孚孟拉羅股份公司 |
經ｐｄ－１調節之ｉｌ－２免疫結合物及其用途
|
|
WO2024243355A1
(en)
|
2023-05-24 |
2024-11-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
|
|
CN121241068A
(zh)
|
2023-06-01 |
2025-12-30 |
豪夫迈·罗氏有限公司 |
靶向bcma和cd28的双特异性抗体
|
|
AR132805A1
(es)
|
2023-06-01 |
2025-07-30 |
Hoffmann La Roche |
Moléculas de unión al antígeno inmunoestimuladoras que se unen específicamente a bcma
|
|
WO2024254455A1
(en)
|
2023-06-08 |
2024-12-12 |
Genentech, Inc. |
Macrophage signatures for diagnostic and therapeutic methods for lymphoma
|
|
CN121311247A
(zh)
|
2023-06-09 |
2026-01-09 |
舒泰神（北京）生物制药股份有限公司 |
特异性结合masp3的抗体以及特异性结合masp3和masp2的多特异性抗体
|
|
CN121358781A
(zh)
|
2023-06-16 |
2026-01-16 |
江苏贝捷泰生物科技有限公司 |
特异性识别因子XIIa的抗体及其应用
|
|
WO2024261013A1
(en)
|
2023-06-21 |
2024-12-26 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|
|
WO2024263761A1
(en)
|
2023-06-22 |
2024-12-26 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
TW202504929A
(zh)
|
2023-06-22 |
2025-02-01 |
美商建南德克公司 |
用於癌症治療之方法及組成物
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
AU2024300009A1
(en)
|
2023-07-21 |
2026-01-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies that broadly target coronaviruses
|
|
WO2025024265A1
(en)
|
2023-07-21 |
2025-01-30 |
Bristol-Myers Squibb Company |
Methods of assessing citrullination and activity of pad4 modulators
|
|
CN121548587A
(zh)
|
2023-07-24 |
2026-02-17 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
WO2025032069A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
AU2024322991A1
(en)
|
2023-08-09 |
2026-01-08 |
F. Hoffmann-La Roche Ag |
Anti-a-beta protein antibodies, methods and uses thereof
|
|
CN121666400A
(zh)
|
2023-08-09 |
2026-03-13 |
豪夫迈·罗氏有限公司 |
单特异性和多特异性抗trem2抗体、其方法和用途
|
|
WO2025038492A1
(en)
|
2023-08-11 |
2025-02-20 |
Abalytics Oncology, Inc. |
Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
|
|
WO2025045251A2
(en)
|
2023-09-03 |
2025-03-06 |
Kira Pharmaceuticals (Us) Llc |
Multispecific constructs comprising anti-factor d moiety
|
|
WO2025064539A1
(en)
|
2023-09-19 |
2025-03-27 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Herv-e antibodies and methods of their use
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
EP4537907A1
(en)
|
2023-10-10 |
2025-04-16 |
Enthera S.r.l. |
Cd248 inhibitors and uses thereof
|
|
WO2025085489A1
(en)
|
2023-10-17 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
|
|
TW202517674A
(zh)
|
2023-10-19 |
2025-05-01 |
德商拜耳廠股份有限公司 |
抗gpc3抗體及其放射性結合物
|
|
WO2025099120A1
(en)
|
2023-11-09 |
2025-05-15 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies with conditional activity
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2025106427A1
(en)
|
2023-11-14 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
|
|
WO2025111402A1
(en)
|
2023-11-21 |
2025-05-30 |
Board Of Regents Of The University Of Nebraska |
Anti-amyloid beta antibodies and related compositions and methods thereof
|
|
WO2025117384A1
(en)
|
2023-12-01 |
2025-06-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing influenza hemagglutinin stem-directed antibodies
|
|
WO2025125118A1
(en)
|
2023-12-11 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
US20260071002A1
(en)
|
2023-12-20 |
2026-03-12 |
Hoffmann-La Roche Inc. |
Antibodies binding to ceacam5
|
|
GB202319605D0
(en)
|
2023-12-20 |
2024-01-31 |
argenx BV |
Monovalent binding molecules and methods of use
|
|
US20250230251A1
(en)
|
2023-12-20 |
2025-07-17 |
Bristol-Myers Squibb Company |
Antibodies targeting il-18 receptor beta (il-18rb) and related methods
|
|
WO2025133290A1
(en)
|
2023-12-21 |
2025-06-26 |
Temper Bio |
Protein for immune regulation
|
|
WO2025137284A2
(en)
|
2023-12-21 |
2025-06-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
WO2025174974A1
(en)
|
2024-02-14 |
2025-08-21 |
Bristol-Myers Squibb Company |
Anti-cd33 antibodies and uses thereof
|
|
WO2025179281A1
(en)
|
2024-02-23 |
2025-08-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of cardiovascular disease with antxr1 antibodies
|
|
WO2025184416A1
(en)
|
2024-02-27 |
2025-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single-domain antibodies and bispecific antibodies against hiv-1 and their use
|
|
WO2025184421A1
(en)
|
2024-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025199352A2
(en)
|
2024-03-20 |
2025-09-25 |
Juno Therapeutics, Inc. |
Antibodies specific for solute carrier family 34 member 2 (slc34a2)
|
|
CA3249015A1
(en)
|
2024-03-20 |
2025-10-31 |
Janssen Biotech, Inc. |
Methods of treating crohn’s disease with anti-il23 specific antibody
|
|
WO2025196639A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody-drug conjugates, and uses thereof
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025226808A1
(en)
|
2024-04-24 |
2025-10-30 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2025229224A1
(en)
|
2024-05-03 |
2025-11-06 |
argenx BV |
Monovalent anti-iga binding molecules and methods of use
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2025238187A1
(en)
|
2024-05-15 |
2025-11-20 |
Cis Biopharma Ag |
Immunoconjugates targeting l1-cam
|
|
WO2025242909A1
(en)
|
2024-05-24 |
2025-11-27 |
Paul Scherrer Institut |
CD30-targeting antibody-radioligand conjugates and their therapeutic use
|
|
WO2025250969A1
(en)
|
2024-05-31 |
2025-12-04 |
Vertex Pharmaceuticals Incorporated |
Anti-cd74 antibodies, conjugates and uses thereof
|
|
WO2025262564A1
(en)
|
2024-06-17 |
2025-12-26 |
Pfizer Inc. |
Use of anti-cxcr5 antibodies
|
|
WO2025262604A1
(en)
|
2024-06-17 |
2025-12-26 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026003761A1
(en)
|
2024-06-27 |
2026-01-02 |
Janssen Biotech, Inc. |
Methods of treating ulcerative colits with anti-il23 specific antibody
|
|
WO2026013218A1
(en)
|
2024-07-10 |
2026-01-15 |
Ac Immune Sa |
Anti-tdp-43 vectors, binding molecules and uses thereof
|
|
EP4684803A1
(en)
|
2024-07-25 |
2026-01-28 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Antibody conjugated chemical inducers of degradation of rbm39 and therapeutic uses thereof
|
|
WO2026030464A1
(en)
|
2024-07-30 |
2026-02-05 |
Genentech, Inc. |
Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
|
|
WO2026030473A1
(en)
|
2024-07-31 |
2026-02-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
West nile virus neutralizing monoclonal antibodies
|
|
WO2026041568A1
(en)
|
2024-08-20 |
2026-02-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and dotam
|
|
WO2026050244A1
(en)
|
2024-08-26 |
2026-03-05 |
Angitia Incorporated Limited |
Methods of treating or preventing osteoporosis and low bone mass
|